

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

**CONVENIENCE TRANSLATION INTO ENGLISH OF  
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE INTERIM PERIOD 1 JANUARY – 30 June 2020  
(ORIGINALLY ISSUED IN TURKISH)**

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS  
ORIGINALLY ISSUED IN TURKISH  
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES  
CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS  
FOR THE INTERIM PERIOD 1 JANUARY - 30 JUNE 2020**

---

| <b>CONTENTS</b>                                                                   | <b>PAGE(S)</b> |
|-----------------------------------------------------------------------------------|----------------|
| <b>CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION.....</b>                | <b>1-2</b>     |
| <b>CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS.....</b>                   | <b>3</b>       |
| <b>CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME.....</b>       | <b>4</b>       |
| <b>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY .....</b> | <b>5</b>       |
| <b>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW .....</b>                       | <b>6-7</b>     |
| <b>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.....</b>              | <b>8-39</b>    |
| NOTE 1 ORGANIZATION AND OPERATIONS OF THE GROUP .....                             | 8-9            |
| NOTE 2 BASIS OF PRESENTATION OF FINANCIAL STATEMENTS .....                        | 9-13           |
| NOTE 3 SEGMENTAL INFORMATION .....                                                | 13             |
| NOTE 4 CASH AND CASH EQUIVALENTS .....                                            | 14             |
| NOTE 5 FINANCIAL INVESTMENTS.....                                                 | 14             |
| NOTE 6 FINANCIAL LIABILITIES.....                                                 | 15-16          |
| NOTE 7 TRADE RECEIVABLES AND PAYABLES.....                                        | 17             |
| NOTE 8 OTHER RECEIVABLES AND PAYABLES.....                                        | 18             |
| NOTE 9 DERIVATIVE INSTRUMENTS.....                                                | 18             |
| NOTE 10 INVENTORIES .....                                                         | 19             |
| NOTE 11 INVESTMENT PROPERTIES.....                                                | 19             |
| NOTE 12 TANGIBLE ASSETS .....                                                     | 20-22          |
| NOTE 13 GOODWILL .....                                                            | 22             |
| NOTE 14 INTANGIBLE ASSETS .....                                                   | 23-24          |
| NOTE 15 OTHER PROVISIONS, CONTINGENT ASSETS AND LIABILITIES.....                  | 24-25          |
| NOTE 16 REVENUE AND COST OF SALES .....                                           | 25             |
| NOTE 17 EXPENSES BY NATURE .....                                                  | 26             |
| NOTE 18 INCOME AND EXPENSES FROM INVESTMENT ACTIVITIES .....                      | 26             |
| NOTE 19 FINANCIAL INCOME .....                                                    | 27             |
| NOTE 20 FINANCIAL EXPENSES.....                                                   | 27             |
| NOTE 21 TAX ASSET AND LIABILITIES .....                                           | 27-30          |
| NOTE 22 EARNINGS PER SHARE .....                                                  | 31             |
| NOTE 23 BALANCES AND TRANSACTIONS WITH RELATED PARTIES .....                      | 31-35          |
| NOTE 24 NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENTS .....        | 36-38          |
| NOTE 25 FINANCIAL INSTRUMENTS .....                                               | 38-39          |
| NOTE 26 EVENTS AFTER THE BALANCE SHEET DATE.....                                  | 39             |

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS**  
**ORIGINALLY ISSUED IN TURKISH**  
**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**  
INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS OF 30 JUNE 2020  
AND 31 DECEMBER 2019  
(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

|                            |              | <b>Condensed<br/>Reviewed<br/>Current<br/>Period<br/>30 June<br/>2020</b> | <b>Audited<br/>Previous<br/>Period<br/>31 December<br/>2019</b> |
|----------------------------|--------------|---------------------------------------------------------------------------|-----------------------------------------------------------------|
| <b>ASSETS</b>              | <b>Notes</b> |                                                                           |                                                                 |
| <b>Current Assets</b>      |              | <b>10.298.815</b>                                                         | <b>8.720.108</b>                                                |
| Cash and Cash Equivalents  | 2.3, 4       | 2.956.000                                                                 | 2.027.599                                                       |
| Financial Investments      | 2.3, 5       | 3.605.728                                                                 | 3.057.459                                                       |
| Trade Receivables          |              |                                                                           |                                                                 |
| - Due From Related Parties | 7-23         | 2.296.692                                                                 | 2.106.741                                                       |
| - Other Trade Receivables  | 7            | 280.550                                                                   | 259.061                                                         |
| Other Receivables          |              |                                                                           |                                                                 |
| - Due From Related Parties | 8-23         | 115.748                                                                   | 115.619                                                         |
| - Other Receivables        | 8            | 43.178                                                                    | 37.283                                                          |
| Derivative Instruments     | 9            | -                                                                         | 358.919                                                         |
| Inventories                | 10           | 804.703                                                                   | 592.698                                                         |
| Prepaid Expenses           |              |                                                                           |                                                                 |
| - Due To Related Parties   | 23           | 44.307                                                                    | 41.545                                                          |
| - Other Prepaid Expenses   |              | 82.356                                                                    | 42.946                                                          |
| Current Income Tax Assets  |              | 198                                                                       | 4.583                                                           |
| Other Current Assets       |              | 69.355                                                                    | 75.655                                                          |
| <b>Non-Current Assets</b>  |              | <b>4.347.719</b>                                                          | <b>4.071.644</b>                                                |
| Financial Investments      | 5            | 1.108.045                                                                 | 946.029                                                         |
| Other Receivables          |              |                                                                           |                                                                 |
| - Other Receivables        | 8            | 344                                                                       | 460                                                             |
| Investment Properties      | 11           | 21.155                                                                    | 21.155                                                          |
| Tangible Assets            | 12           | 2.418.095                                                                 | 2.383.177                                                       |
| Intangible Assets          |              |                                                                           |                                                                 |
| - Goodwill                 | 13           | 420.567                                                                   | 388.047                                                         |
| - Other Intangible Assets  | 14           | 333.876                                                                   | 292.188                                                         |
| Prepaid Expenses           |              | 11.362                                                                    | 7.602                                                           |
| Deferred Tax Asset         | 21           | 34.275                                                                    | 32.986                                                          |
| <b>TOTAL ASSETS</b>        |              | <b>14.646.534</b>                                                         | <b>12.791.752</b>                                               |

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS**  
**ORIGINALLY ISSUED IN TURKISH**  
**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**  
INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS OF 30 JUNE 2020  
AND 31 DECEMBER 2019  
(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

|                                                                                         |              | <b>Condensed<br/>Reviewed<br/>Current<br/>Period<br/>30 June<br/>2020</b> | <b>Audited<br/>Previous<br/>Period<br/>31 December<br/>2019</b> |
|-----------------------------------------------------------------------------------------|--------------|---------------------------------------------------------------------------|-----------------------------------------------------------------|
| <b>LIABILITIES</b>                                                                      | <b>Notes</b> |                                                                           |                                                                 |
| <b>Current Liabilities</b>                                                              |              | <b>4.960.025</b>                                                          | <b>6.800.011</b>                                                |
| Short Term Financial Liabilities                                                        | 6            | 115.995                                                                   | 150.764                                                         |
| Short Term Portion of Long-Term Financial Liabilities                                   | 6            | 3.364.123                                                                 | 5.088.239                                                       |
| Trade Payables                                                                          |              |                                                                           |                                                                 |
| - Due to related parties                                                                | 7-23         | 398.629                                                                   | 607.365                                                         |
| - Other trade payables                                                                  | 7            | 555.870                                                                   | 617.233                                                         |
| Employee Benefit Related Liabilities                                                    |              | 53.185                                                                    | 44.822                                                          |
| Other Payables                                                                          |              |                                                                           |                                                                 |
| - Due to Related Parties                                                                | 8-23         | 1.523                                                                     | 113                                                             |
| - Other Payables                                                                        | 8            | 3.161                                                                     | 4.994                                                           |
| Derivative Instruments                                                                  | 9            | 781                                                                       | -                                                               |
| Deferred Revenue                                                                        |              | 9.887                                                                     | 11.854                                                          |
| Current Income Tax Liabilities                                                          | 21           | 143.905                                                                   | 68.967                                                          |
| Short Term Provisions                                                                   |              |                                                                           |                                                                 |
| - Short Term Provisions for Employee Benefits                                           |              | 64.370                                                                    | 66.366                                                          |
| - Other Short-Term Provisions                                                           |              | 212.344                                                                   | 103.331                                                         |
| Other Current Liabilities                                                               |              | 36.252                                                                    | 35.963                                                          |
| <b>Non-Current Liabilities</b>                                                          |              | <b>4.057.727</b>                                                          | <b>1.057.509</b>                                                |
| Long Term Financial Liabilities                                                         | 6            | 3.753.105                                                                 | 701.318                                                         |
| Long Term Provisions                                                                    |              |                                                                           |                                                                 |
| - Long Term Provisions for Employee Benefits                                            |              | 186.693                                                                   | 161.010                                                         |
| Deferred Tax Liabilities                                                                | 21           | 117.929                                                                   | 195.181                                                         |
| <b>SHAREHOLDERS' EQUITY</b>                                                             |              | <b>5.628.782</b>                                                          | <b>4.934.232</b>                                                |
| <b>Equity Attributable To Equity Holders' of the Parent</b>                             |              | <b>4.970.991</b>                                                          | <b>4.411.329</b>                                                |
| Share Capital                                                                           |              | 342.000                                                                   | 342.000                                                         |
| Inflation Adjustments to Share Capital                                                  |              | 108.056                                                                   | 108.056                                                         |
| Effect of Business Combinations Under Common Control                                    |              | (485.419)                                                                 | (485.419)                                                       |
| Other Comprehensive Income/Expense not to be Reclassified to Profit and Loss            |              |                                                                           |                                                                 |
| - Increases on Revaluation of Plant, Property and Equipment                             |              | 647.779                                                                   | 647.779                                                         |
| - Actuarial Losses on Post-Employment Termination Benefit Obligation                    |              | (28.751)                                                                  | (26.435)                                                        |
| - Gains from Financial Assets Measured at Fair Value through Other Comprehensive Income | 2.3          | 573.766                                                                   | 422.738                                                         |
| - Other Gains                                                                           |              | 817.879                                                                   | 817.879                                                         |
| Other Comprehensive Income/Expense to be Reclassified to Profit and Loss                |              |                                                                           |                                                                 |
| - Currency Translation Adjustments                                                      |              | (47.703)                                                                  | (57.006)                                                        |
| - Cash Flow Hedges                                                                      |              | (809)                                                                     | 3.695                                                           |
| Restricted Reserves                                                                     |              | 131.587                                                                   | 131.587                                                         |
| Retained Earnings                                                                       |              | 2.506.455                                                                 | 1.509.952                                                       |
| Net Profit for the Period                                                               | 2.3          | 406.151                                                                   | 996.503                                                         |
| Non-Controlling Interest                                                                |              | 657.791                                                                   | 522.903                                                         |
| <b>TOTAL LIABILITIES AND EQUITY</b>                                                     |              | <b>14.646.534</b>                                                         | <b>12.791.752</b>                                               |

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**  
**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS FOR THE INTERIM PERIOD ENDED 30 JUNE 2020 AND 2019**  
(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

|                                                                  | Notes | Condensed<br>Reviewed<br>Current Period<br>1 January - 30 June<br>2020 | Condensed<br>Unaudited<br>Current Period<br>1 April - 30 June<br>2020 | Condensed<br>Reviewed<br>Previous Period<br>1 January - 30 June<br>2019 | Condensed<br>Unaudited<br>Previous Period<br>1 April - 30 June<br>2019 |
|------------------------------------------------------------------|-------|------------------------------------------------------------------------|-----------------------------------------------------------------------|-------------------------------------------------------------------------|------------------------------------------------------------------------|
| Revenue                                                          | 16    | 4.520.767                                                              | 2.144.641                                                             | 3.762.858                                                               | 1.820.498                                                              |
| Cost of Sales                                                    | 16    | (3.217.351)                                                            | (1.557.506)                                                           | (2.715.520)                                                             | (1.311.332)                                                            |
| <b>GROSS PROFIT</b>                                              |       | <b>1.303.416</b>                                                       | <b>587.135</b>                                                        | <b>1.047.338</b>                                                        | <b>509.166</b>                                                         |
| General Administrative Expenses                                  | 17    | (127.624)                                                              | (63.808)                                                              | (94.585)                                                                | (55.972)                                                               |
| Marketing, Sales and Distribution Expenses                       | 17    | (459.455)                                                              | (183.824)                                                             | (379.650)                                                               | (172.846)                                                              |
| Research and Development Expenses                                | 17    | (11.176)                                                               | (5.494)                                                               | (9.089)                                                                 | (5.253)                                                                |
| Other Operating Income                                           |       | 97.242                                                                 | 42.459                                                                | 48.155                                                                  | 16.379                                                                 |
| Other Operating Expenses                                         |       | (61.805)                                                               | (33.077)                                                              | (37.688)                                                                | (13.374)                                                               |
| <b>OPERATING PROFIT</b>                                          |       | <b>740.598</b>                                                         | <b>343.391</b>                                                        | <b>574.481</b>                                                          | <b>278.100</b>                                                         |
| Income from Investment Activities                                | 18    | 1.044.715                                                              | 319.477                                                               | 696.531                                                                 | 143.209                                                                |
| Expenses from Investment Activities                              | 18    | (243.204)                                                              | 429.124                                                               | (10.261)                                                                | 14.794                                                                 |
| <b>OPERATING PROFIT BEFORE FINANCIAL<br/>INCOME AND EXPENSES</b> |       | <b>1.542.109</b>                                                       | <b>1.091.992</b>                                                      | <b>1.260.751</b>                                                        | <b>436.103</b>                                                         |
| Financial Income                                                 | 19    | 189.838                                                                | 182.141                                                               | 84.619                                                                  | 82.614                                                                 |
| Financial Expenses                                               | 20    | (1.120.446)                                                            | (592.053)                                                             | (680.303)                                                               | (357.923)                                                              |
| <b>PROFIT BEFORE TAX</b>                                         |       | <b>611.501</b>                                                         | <b>682.080</b>                                                        | <b>665.067</b>                                                          | <b>160.794</b>                                                         |
| <b>Tax Expense</b>                                               |       | <b>(116.170)</b>                                                       | <b>(142.606)</b>                                                      | <b>(119.687)</b>                                                        | <b>(14.860)</b>                                                        |
| Corporate Tax Expense                                            | 21    | (201.400)                                                              | (134.062)                                                             | (115.593)                                                               | (6.824)                                                                |
| Deferred Tax Income/(Expenses)                                   | 21    | 85.230                                                                 | (8.544)                                                               | (4.094)                                                                 | (8.036)                                                                |
| <b>PROFIT FOR THE PERIOD</b>                                     |       | <b>495.331</b>                                                         | <b>539.474</b>                                                        | <b>545.380</b>                                                          | <b>145.934</b>                                                         |
| <b>Distribution of the Profit for the Period</b>                 |       |                                                                        |                                                                       |                                                                         |                                                                        |
| Non-Controlling Interest                                         |       | 89.180                                                                 | 35.031                                                                | 58.171                                                                  | 24.201                                                                 |
| Equity Holders of the Parent                                     |       | 406.151                                                                | 504.443                                                               | 487.209                                                                 | 121.733                                                                |
| Earnings Per Share                                               | 22    | 1,19                                                                   | 1,47                                                                  | 1,42                                                                    | 0,36                                                                   |

**CONVENIENCE TRANSLATION INTO ENGLISH OF  
CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH  
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME FOR THE INTERIM PERIODS ENDED 30 JUNE 2020 AND 2019

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

|                                                                                                      | Condensed<br>Reviewed<br>Current Period<br>1 January - 30 June<br>2020 | Condensed<br>Unaudited<br>Current Period<br>1 April - 30 June<br>2020 | Condensed<br>Reviewed<br>Previous Period<br>1 January - 30 June<br>2019 | Condensed<br>Unaudited<br>Previous Period<br>1 April - 30 June<br>2019 |
|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|-----------------------------------------------------------------------|-------------------------------------------------------------------------|------------------------------------------------------------------------|
| <b>PROFIT FOR THE PERIOD</b>                                                                         | <b>495.331</b>                                                         | <b>539.474</b>                                                        | <b>545.380</b>                                                          | <b>145.934</b>                                                         |
| <b>Other Comprehensive Income</b>                                                                    |                                                                        |                                                                       |                                                                         |                                                                        |
| <b>Not to be Reclassified To Profit and Loss</b>                                                     | <b>148.659</b>                                                         | <b>152.165</b>                                                        | <b>348.472</b>                                                          | <b>348.472</b>                                                         |
| Actuarial Loss on Post-Employment<br>Termination Benefit Obligation                                  | (2.974)                                                                | 1.421                                                                 | (170)                                                                   | (170)                                                                  |
| Gains from Financial Assets Measured at Fair Value through<br>Other comprehensive income             | 162.016                                                                | 162.016                                                               | 366.956                                                                 | 366.956                                                                |
| <b>Deferred Tax for the Items That Will not be Reclassified<br/>in Profit and Loss</b>               |                                                                        |                                                                       |                                                                         |                                                                        |
| Actuarial Loss on Post-Employment Termination<br>Loss Obligation, Deferred Tax Effect                | 595                                                                    | (284)                                                                 | 34                                                                      | 34                                                                     |
| Gains from Financial Assets Measured at Fair Value<br>through Other Comprehensive Income, Tax Effect | (10.988)                                                               | (10.988)                                                              | (18.348)                                                                | (18.348)                                                               |
| <b>Items to be Reclassified to Profit and Loss</b>                                                   | <b>50.570</b>                                                          | <b>7.029</b>                                                          | <b>17.252</b>                                                           | <b>(28.920)</b>                                                        |
| Currency Translation Adjustments                                                                     | 55.074                                                                 | 13.983                                                                | 33.317                                                                  | (2.524)                                                                |
| Cash Flow Hedges                                                                                     | (5.774)                                                                | (8.915)                                                               | (20.596)                                                                | (33.841)                                                               |
| <b>Deferred Tax For The Items That Will be Reclassified to<br/>Profit and Loss</b>                   |                                                                        |                                                                       |                                                                         |                                                                        |
| Cash Flow Hedges, Deferred Tax Effect                                                                | 1.270                                                                  | 1.961                                                                 | 4.531                                                                   | 7.445                                                                  |
| <b>OTHER COMPREHENSIVE INCOME</b>                                                                    | <b>199.219</b>                                                         | <b>159.194</b>                                                        | <b>365.724</b>                                                          | <b>319.552</b>                                                         |
| <b>TOTAL COMPREHENSIVE INCOME</b>                                                                    | <b>694.550</b>                                                         | <b>698.668</b>                                                        | <b>911.104</b>                                                          | <b>465.486</b>                                                         |
| <b>Distribution of Total Comprehensive Income</b>                                                    |                                                                        |                                                                       |                                                                         |                                                                        |
| Non-Controlling Interest                                                                             | 134.888                                                                | 48.628                                                                | 81.665                                                                  | 30.748                                                                 |
| Equity Holders of the Parent                                                                         | 559.662                                                                | 650.040                                                               | 829.439                                                                 | 434.738                                                                |

**CONVENIENCE TRANSLATION INTO ENGLISH OF  
CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH  
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY FOR THE INTERIM PERIODS ENDED 30 JUNE 2020 AND 2019  
(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

|                                             | Accumulated Other Comprehensive Income To Be Reclassified Under Profit And Loss |                                        |                                                      |                                  |                  | Accumulated Other Comprehensive Income Not To Be Reclassified To Profit And Loss |                                                                    |                                                                                    |                |                     | Accumulated Profit        |                   |                                                     |                          |                  |
|---------------------------------------------|---------------------------------------------------------------------------------|----------------------------------------|------------------------------------------------------|----------------------------------|------------------|----------------------------------------------------------------------------------|--------------------------------------------------------------------|------------------------------------------------------------------------------------|----------------|---------------------|---------------------------|-------------------|-----------------------------------------------------|--------------------------|------------------|
|                                             | Share Capital                                                                   | Inflation Adjustments to Share Capital | Effect of Business Combinations Under Common Control | Currency Translation Adjustments | Cash Flow Hedges | Revaluation of Plant, Property and Equipment                                     | Actuarial Losses on Post-Employment Termination Benefit Obligation | Gains from Financial Assets Measured Fair Value Through Other Comprehensive Income | Other Gains    | Restricted Reserves | Net Profit for the Period | Retained Earnings | Equity Attributable to Equity Holders of the Parent | Non-Controlling Interest | Total            |
| <b>As of 1 January, 2019</b>                | <b>342.000</b>                                                                  | <b>108.056</b>                         | <b>(498.670)</b>                                     | <b>(89.429)</b>                  | <b>52.481</b>    | <b>647.779</b>                                                                   | <b>(21.173)</b>                                                    | <b>1.099.942</b>                                                                   | <b>-</b>       | <b>131.587</b>      | <b>700.779</b>            | <b>822.885</b>    | <b>3.296.237</b>                                    | <b>383.495</b>           | <b>3.679.732</b> |
| Transfer                                    | -                                                                               | -                                      | -                                                    | -                                | -                | -                                                                                | -                                                                  | -                                                                                  | -              | 6.798               | (700.779)                 | 693.981           | -                                                   | -                        | -                |
| Total comprehensive income                  | -                                                                               | -                                      | -                                                    | 9.836                            | (16.065)         | -                                                                                | (149)                                                              | 348.608                                                                            | -              | -                   | 487.209                   | -                 | 829.439                                             | 81.665                   | 911.104          |
| <b>As of 30 June 2019</b>                   | <b>342.000</b>                                                                  | <b>108.056</b>                         | <b>(498.670)</b>                                     | <b>(79.593)</b>                  | <b>36.416</b>    | <b>647.779</b>                                                                   | <b>(21.322)</b>                                                    | <b>1.448.550</b>                                                                   | <b>-</b>       | <b>138.385</b>      | <b>487.209</b>            | <b>1.516.866</b>  | <b>4.125.676</b>                                    | <b>465.160</b>           | <b>4.590.836</b> |
| <b>As of 1 January 2020<br/>(Note: 2.3)</b> | <b>342.000</b>                                                                  | <b>108.056</b>                         | <b>(485.419)</b>                                     | <b>(57.006)</b>                  | <b>3.695</b>     | <b>647.779</b>                                                                   | <b>(26.435)</b>                                                    | <b>422.738</b>                                                                     | <b>817.879</b> | <b>131.587</b>      | <b>996.503</b>            | <b>1.509.952</b>  | <b>4.411.329</b>                                    | <b>522.903</b>           | <b>4.934.232</b> |
| Transfer                                    | -                                                                               | -                                      | -                                                    | -                                | -                | -                                                                                | -                                                                  | -                                                                                  | -              | -                   | (996.503)                 | 996.503           | -                                                   | -                        | -                |
| Total comprehensive income                  | -                                                                               | -                                      | -                                                    | 9.303                            | (4.504)          | -                                                                                | (2.316)                                                            | 151.028                                                                            | -              | -                   | 406.151                   | -                 | 559.662                                             | 134.888                  | 694.550          |
| <b>As of 30 June 2020</b>                   | <b>342.000</b>                                                                  | <b>108.056</b>                         | <b>(485.419)</b>                                     | <b>(47.703)</b>                  | <b>(809)</b>     | <b>647.779</b>                                                                   | <b>(28.751)</b>                                                    | <b>573.766</b>                                                                     | <b>817.879</b> | <b>131.587</b>      | <b>406.151</b>            | <b>2.506.455</b>  | <b>4.970.991</b>                                    | <b>657.791</b>           | <b>5.628.782</b> |

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS  
ORIGINALLY ISSUED IN TURKISH  
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES  
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE INTERIM PERIODS ENDED  
30 JUNE 2020 AND 2019  
(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)**

|                                                                              |              | <b>Condensed<br/>Reviewed<br/>Current<br/>Period<br/>1 January -<br/>30 June 2020</b> | <b>Condensed<br/>Reviewed<br/>Previous<br/>Period<br/>1 January -<br/>30 June 2019</b> |
|------------------------------------------------------------------------------|--------------|---------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
|                                                                              | <b>Notes</b> |                                                                                       |                                                                                        |
| <b>CASH FLOWS FROM OPERATING ACTIVITIES</b>                                  |              |                                                                                       |                                                                                        |
| Net profit for the period                                                    |              | 495.331                                                                               | 545.380                                                                                |
| <b>Adjustments to Reconcile Net Profit</b>                                   |              |                                                                                       |                                                                                        |
| Adjustment for Depreciation and Amortization Expenses                        |              |                                                                                       |                                                                                        |
| Depreciation expenses of tangible assets                                     | 12           | 88.657                                                                                | 82.148                                                                                 |
| Amortization expenses of intangible assets                                   | 14           | 1.128                                                                                 | 2.616                                                                                  |
| Adjustment for Impairment Loss (Reversal)                                    |              |                                                                                       |                                                                                        |
| Provision for doubtful receivables                                           | 7            | 490                                                                                   | (1.204)                                                                                |
| Adjustment for impairment loss of other<br>financial investments Loss/(gain) |              |                                                                                       |                                                                                        |
| Increase in financial investments                                            | 18           | -                                                                                     | (132.530)                                                                              |
| Decrease in financial investments                                            | 18           | 137.078                                                                               | -                                                                                      |
| Adjustment for impairment loss of inventories                                | 10           | 5.567                                                                                 | 9.158                                                                                  |
| Adjustment for Provisions                                                    |              |                                                                                       |                                                                                        |
| Adjustments for Provisions Related with<br>Employee Benefits                 |              |                                                                                       |                                                                                        |
| Provision for employment benefits                                            |              | 25.718                                                                                | 24.613                                                                                 |
| Provision for unused vacation                                                |              | 13.910                                                                                | 5.945                                                                                  |
| Provision for premium                                                        |              | 21.450                                                                                | 20.070                                                                                 |
| Adjustments for provisions (cancelled) lawsuits                              |              | 129                                                                                   | 722                                                                                    |
| Adjustments for Other Provisions                                             |              |                                                                                       |                                                                                        |
| Change in Other Provisions (net)                                             |              | 109.320                                                                               | 124.317                                                                                |
| Adjustments for Dividend Income                                              |              | (64)                                                                                  | (83)                                                                                   |
| Adjustments for Interest Income and Expense                                  |              |                                                                                       |                                                                                        |
| Adjustments Interest Income                                                  | 18           | (61.565)                                                                              | (123.358)                                                                              |
| Adjustments for Interest Expense                                             |              |                                                                                       |                                                                                        |
| Interest Expense                                                             | 20           | 185.961                                                                               | 199.575                                                                                |
| Rediscounted Interest Expense (net)                                          |              | 190                                                                                   | 1.448                                                                                  |
| Adjustment for Tax Expenses                                                  | 21           | 116.170                                                                               | 119.687                                                                                |
| Adjustments for Losses (Gains) on Disposals of<br>Non-Current Assets         |              |                                                                                       |                                                                                        |
| Adjustments for Gains Arised from Sale of<br>Tangible Assets                 | 18           | (1.137)                                                                               | 1.277                                                                                  |
| Adjustments for Investing and Financing Cash Flow                            |              |                                                                                       |                                                                                        |
| Change in foreign currency of financial liabilities (net)                    | 19-20        | 726.636                                                                               | 382.507                                                                                |
| Change in foreign currency from investing activities (net)                   | 18           | (869.848)                                                                             | (426.433)                                                                              |
| Commission expenses and financial service income (net)                       | 19-20        | 18.011                                                                                | 13.602                                                                                 |
| Other Adjustments to Reconcile Profit/(Loss)                                 |              |                                                                                       |                                                                                        |
| Rent income                                                                  | 18           | (5.975)                                                                               | (5.143)                                                                                |
| <b>Net operating cash flows provided before changes in working capital</b>   |              | <b>1.007.157</b>                                                                      | <b>844.314</b>                                                                         |

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS**  
**ORIGINALLY ISSUED IN TURKISH**  
**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE INTERIM PERIODS ENDED**  
**30 JUNE 2020 AND 2019**  
(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

|                                                           |              | <b>Condensed<br/>Reviewed<br/>Current<br/>Period<br/>1 January -<br/>30 June 2020</b> | <b>Condensed<br/>Reviewed<br/>Previous<br/>Period<br/>1 January -<br/>30 June 2019</b> |
|-----------------------------------------------------------|--------------|---------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
|                                                           | <b>Notes</b> |                                                                                       |                                                                                        |
| <b>Changes in Working Capital</b>                         |              |                                                                                       |                                                                                        |
| Decrease/(increase) in trade receivables                  |              | 28.051                                                                                | (60.857)                                                                               |
| Increase in trade receivables from related parties        |              | (189.951)                                                                             | (321.682)                                                                              |
| Increase in inventories                                   |              | (189.483)                                                                             | (42.648)                                                                               |
| Increase in other receivables and other current assets    |              | (35.315)                                                                              | (5.731)                                                                                |
| Decrease in trade payables                                |              | (104.190)                                                                             | (115.881)                                                                              |
| (Decrease)/Increase in trade payables to related parties  |              | (208.736)                                                                             | 45.652                                                                                 |
| Decrease in other payables and liabilities                |              | (10.281)                                                                              | (22.850)                                                                               |
| <b>Net cash generated from operations</b>                 |              | <b>297.252</b>                                                                        | <b>320.317</b>                                                                         |
| Payments related with provisions for employee benefits    |              |                                                                                       |                                                                                        |
| Employment termination benefit paid                       |              |                                                                                       |                                                                                        |
| Unused vacation paid                                      |              | (9.746)                                                                               | (7.737)                                                                                |
| Performance premium paid                                  |              | (10.643)                                                                              | (3.320)                                                                                |
| Payments related with provisions for employee benefits    |              | (37.667)                                                                              | (30.190)                                                                               |
| Lawsuits provision paid                                   |              | (196)                                                                                 | (225)                                                                                  |
| Taxes paid                                                |              | (122.077)                                                                             | (67.739)                                                                               |
| Collections from doubtful trade receivables               | 7            | 143                                                                                   | 367                                                                                    |
| <b>Net cash generated from operating activities</b>       |              | <b>117.066</b>                                                                        | <b>211.473</b>                                                                         |
| <b>CASH FLOWS FROM INVESTING ACTIVITIES</b>               |              |                                                                                       |                                                                                        |
| Proceeds from sales of tangible and intangible assets     |              | 2.637                                                                                 | 6.693                                                                                  |
| Purchase of property, plant and equipment                 |              | (49.924)                                                                              | (47.911)                                                                               |
| Purchase of intangible assets                             |              | (2.099)                                                                               | (1.670)                                                                                |
| Changes in non-trade receivables from related parties     | 23           | (129)                                                                                 | (87)                                                                                   |
| Cash generated from dividends                             |              | 64                                                                                    | 83                                                                                     |
| Interest received                                         |              | 61.565                                                                                | 123.358                                                                                |
| Repayments from given other advances and payables         |              | (3.760)                                                                               | -                                                                                      |
| Repayments from given other advances and payables         |              | -                                                                                     | 784                                                                                    |
| Rent Income                                               |              | 5.975                                                                                 | 5.143                                                                                  |
| Proceeds from sales of other businesses or share of       |              |                                                                                       |                                                                                        |
| Funds or debt instruments                                 |              | -                                                                                     | 703.819                                                                                |
| Cash outflows from purchase of other businesses or        |              |                                                                                       |                                                                                        |
| share of funds or debt instruments                        |              | (105.796)                                                                             | -                                                                                      |
| <b>Net cash generated from investing activities</b>       |              | <b>(91.467)</b>                                                                       | <b>790.212</b>                                                                         |
| <b>CASH FLOWS FROM FINANCING ACTIVITIES</b>               |              |                                                                                       |                                                                                        |
| Cash inflow from borrowings                               |              | 3.123.611                                                                             | 206.719                                                                                |
| Repayments of borrowings                                  |              | (2.733.053)                                                                           | (57.102)                                                                               |
| Cash inflow from derivate instruments                     |              | 500.271                                                                               | -                                                                                      |
| Commission paid                                           |              | (18.011)                                                                              | (13.602)                                                                               |
| Interest paid                                             |              | (175.205)                                                                             | (194.884)                                                                              |
| Change in non-trade payables to related parties           | 23           | 1.410                                                                                 | (821)                                                                                  |
| <b>Net cash generated/(used)from financing activities</b> |              | <b>699.023</b>                                                                        | <b>(59.690)</b>                                                                        |
| <b>NET CHANGE IN CASH AND CASH EQUIVALENTS</b>            |              | <b>724.622</b>                                                                        | <b>941.995</b>                                                                         |
| <b>THE EFFECT OF FOREIGN EXCHANGE RATE</b>                |              |                                                                                       |                                                                                        |
| <b>CHANGE ON CASH AND CASH EQUIVALENTS</b>                |              | <b>203.779</b>                                                                        | <b>90.985</b>                                                                          |
| <b>CASH AND CASH EQUIVALENTS AT THE</b>                   |              |                                                                                       |                                                                                        |
| <b>BEGINNING OF THE PERIOD</b>                            | 4            | <b>2.027.599</b>                                                                      | <b>999.462</b>                                                                         |
| <b>CASH AND CASH EQUIVALENTS AT THE END OF</b>            |              |                                                                                       |                                                                                        |
| <b>THE PERIOD</b>                                         | 4            | <b>2.956.000</b>                                                                      | <b>2.032.442</b>                                                                       |

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS  
ORIGINALLY ISSUED IN TURKISH  
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD  
ENDED 30 JUNE 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**1. ORGANIZATION AND OPERATIONS OF THE GROUP**

Ülker Bisküvi Sanayi A.Ş. ("the Company") and its subsidiaries (all together "the Group"), comprises of the parent Ülker Bisküvi Sanayi A.Ş. ("the Company") and fourteen subsidiaries in which the Company owns the majority share of the capital or which are controlled by the Company (2019: Fourteen).

Ülker Bisküvi Sanayi A.Ş. was established in 1944. The Company's core business activities are manufacturing of biscuits, chocolate, chocolate coated biscuits, wafers and cakes.

Ülker Bisküvi Sanayi A.Ş. which is registered at the Capital Market Board, merged under its own title with Anadolu Gıda Sanayi A.Ş., whose shares have been quoted on Borsa İstanbul since 30 October 1996, as of 31 December 2003.

The headquarter of Ülker Bisküvi Sanayi A.Ş. is located Kısıklı Mah. Ferah Cad. No:1 Büyük Çamlıca Üsküdar/İstanbul.

As of 30 June 2020, the total number of people employed by the Group is 9.204, which contains 1.515 employees who worked as subcontractors (31 December 2019: 8.921, subcontractor: 1.276).

The ultimate parent and the controlling party of the Group is pladis Foods Limited. The ultimate controlling party is Yıldız Holding A.Ş.. pladis Foods Limited is subsidiary of Yıldız Holding A.Ş. with a shares of 100%. Yıldız Holding A.Ş. is managed by Ülker Family.

As of 30 June 2020 and 31 December 2019, the names and percentages of the shareholders holding more than 5% of the Company's share capital are as follows:

| Name of the Shareholders                     | Share          | 30 June 2020   | Share          | 31 December 2019 |
|----------------------------------------------|----------------|----------------|----------------|------------------|
|                                              |                | Percentage     |                | Percentage       |
| pladis Foods Limited                         | 174.420        | %51,00         | 174.420        | %51,00           |
| Ülker Family Members and Yıldız Holding A.Ş. | 25.580         | %7,48          | 25.580         | %7,48            |
| Other                                        | 142.000        | %41,52         | 142.000        | %41,52           |
|                                              | <b>342.000</b> | <b>%100,00</b> | <b>342.000</b> | <b>%100,00</b>   |

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS  
ORIGINALLY ISSUED IN TURKISH  
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD  
ENDED 30 JUNE 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**1. ORGANIZATION AND OPERATIONS OF THE GROUP (Continued)**

As of 30 June 2020 and 31 December 2019, the details of the subsidiaries under consolidation in terms of direct and effective share of ownership and principal business activities are as follows:

| Subsidiaries                                | 30 June 2020              |                              | 31 December 2019          |                              | Nature of Operation |
|---------------------------------------------|---------------------------|------------------------------|---------------------------|------------------------------|---------------------|
|                                             | Ratio of Direct Ownership | Ratio of Effective Ownership | Ratio of Direct Ownership | Ratio of Effective Ownership |                     |
| Biskot Bisküvi Gıda Sanayi ve Ticaret A.Ş.  | %73,9                     | %73,9                        | %73,9                     | %73,9                        | Manufacturing       |
| Ülker Çikolata Sanayi A.Ş.                  | %91,7                     | %91,7                        | %91,7                     | %91,7                        | Manufacturing       |
| Atlas Gıda Pazarlama Sanayi ve Ticaret A.Ş. | %100,0                    | %100,0                       | %100,0                    | %100,0                       | Trading             |
| Reform Gıda Paz. San. ve Tic. A.Ş.          | %100,0                    | %100,0                       | %100,0                    | %100,0                       | Trading             |
| UI Egypt B.V.                               | %51,0                     | %51,0                        | %51,0                     | %51,0                        | Investing           |
| Hi-Food for Advanced Food Industries        | -                         | %51,4                        | -                         | %51,4                        | Manufacturing/Sales |
| Sabourne Investments Ltd                    | %100,0                    | %100,0                       | %100,0                    | %100,0                       | Investing           |
| Food Manufacturers' Company                 | -                         | %55,0                        | -                         | %55,0                        | Manufacturing/Sales |
| Hamle Company Ltd LLP                       | %100,0                    | %100,0                       | %100,0                    | %100,0                       | Manufacturing/Sales |
| Ulker Star LLC                              | -                         | %99,0                        | -                         | %99,0                        | Sales               |
| UI Mena BV                                  | %100,0                    | %100,0                       | %100,0                    | %100,0                       | Investing           |
| Amir Global Trading FZE                     | -                         | %100,0                       | -                         | %100,0                       | Sales               |
| Ulker for Trading and Marketing             | -                         | %99,8                        | -                         | %99,8                        | Sales               |
| International Biscuits Company              | %100,0                    | %100,0                       | %100,0                    | %100,0                       | Manufacturing/Sales |

Approval of Financial Statements:

The Board of Directors has approved the financial statements and given authorization for the issuance on 6 August 2020.

**2. BASIS OF PRESENTATION OF FINANCIAL STATEMENTS**

**2.1 Basis of Presentation:**

**Principles for Preparation of Financial Statements and Significant Accounting Policies**

The accompanying consolidated financial statements are prepared in accordance with Communiqué Serial II, No:14.1, "Principles of Financial Reporting in Capital Markets" ("the Communiqué") published in the Official Gazette numbered 28676 on 13 June 2013. According to Article 5 of the Communiqué, consolidated financial statements are prepared in accordance with the Turkish Accounting Standards ("TAS") issued by Public Oversight Accounting and Auditing Standards Authority ("POAASA"). TAS contains Turkish Accounting Standards, Turkish Financial Reporting Standards ("TFRS") and its addendum and interpretations.

The consolidated financial statements of the Group are prepared as per the CMB announcement of 7 June 2013 relating to financial statements presentations.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS  
ORIGINALLY ISSUED IN TURKISH  
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD  
ENDED 30 JUNE 2020**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise stated)

**2. BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)**

**2.1 Basis of the Presentation (Continued)**

**Principles for Preparation of Financial Statements and Significant Accounting Policies (Continued)**

In accordance with the CMB resolution issued on 17 March 2005, listed companies operating in Turkey are not subject to inflation accounting effective from 1 January 2005. Therefore, the consolidated financial statements of the Group have been prepared accordingly.

The Company and Subsidiaries in Turkey maintain their books of accounts and prepare their statutory financial statements in accordance with the Turkish Commercial Code (“TCC”), tax legislation, the Uniform Chart of Accounts issued by the Ministry of Finance and principles issued by CMB. The foreign subsidiaries maintain their books of account in accordance with the laws and regulations in force in the countries in which they are registered. These consolidated financial statements have been prepared under historical cost conventions except for land, buildings, financial assets and financial liabilities which are carried at fair value. The consolidated financial statements are based on the statutory records, which are maintained under historical cost conventions.

In accordance with the TAS, the entities are allowed to prepare a complete or condensed set of interim financial statements in accordance with TAS 34, “Interim Financial Reporting”. In this respect, the Group preferred to present its interim condensed consolidated financial statements. The Group’s interim condensed consolidated financial statement does not include all disclosures and notes that should be included at year-end financial statements. Therefore, the interim condensed consolidated financial statements should be examined together with the 31 December 2019 and 31 December 2018 year-end financial statements.

**Functional and Presentation Currency**

Financial statements of each subsidiary of the Group are presented in the currency of the primary economic environment in which the entities operate (its functional currency). The results and financial position of each subsidiary are expressed in Turkish Lira, which is the presentation currency of the Group.

As of 30 June 2020, rates declared by Central Bank of Republic of Turkey are;

1 EURO = TL 7,7082, 1 USD = TL 6,8422, 1 EGP = TL 0,4232, 1 Arabian SAR = TL 1,8240, 1 KZT = TL 0,0169, 1 AED = TL 1,8644. (31 December 2019: 1 EURO = TL 6,6506, 1 USD = TL 5,9402, 1 EGP = TL 0,3703, 1 SAR = TL 1,5834, 1 KZT = TL 0,0156, 1 AED = TL 1,6186).

For the period between 1 January 2020 and 30 June 2020, average rates declared by Central Bank of Republic of Turkey are; 1 EURO = TL 7,1303, 1 USD = TL 6,4731, 1 EGP = TL 0,4092, 1 SAR = TL 1,7241, 1 KZT = TL 0,0160, 1 AED = TL 1,7639. (1 January - 30 June 2019: 1 EURO = TL 6,3456, 1 USD = TL 5,6197, 1 EGP = TL 0,3253, 1 SAR = TL 1,4984, 1 KZT = TL 0,0148, 1 AED = TL 1,5313.)

**2.2 The New Standards, Amendments and Interpretations**

The Group has applied the standards which are relevant to its operations from the standards, amendments and interpretation applicable from 1 January 2020.

**Standards, amendments and interpretations applicable as at 30 June 2020:**

Amendments to TAS 1 and TAS 8 on the definition of material; effective from Annual periods beginning on or after 1 January 2020. The amendments did not have a significant impact on the financial position or performance of the Group.

Amendments to TFRS 3 - definition of a business; effective from Annual periods beginning on or after 1 January 2020. The amendments did not have a significant impact on the financial position or performance of the Group.

Amendments to TFRS 9, IAS 39 and TFRS 7 – Interest rate benchmark reform; effective from Annual periods beginning on or after 1 January 2020. The amendments did not have a significant impact on the financial position or performance of the Group.

TFRS 16 – Covid - 19 Rent Related Concessions Leases; effective from Annual periods beginning on or after 1 January 2020. The amendments did not have a significant impact on the financial position or performance of the Group.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS  
ORIGINALLY ISSUED IN TURKISH  
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD  
ENDED 30 JUNE 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

---

**2. BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)**

**2.2 The new standards, amendments and interpretations (Continued)**

**Standards, amendments and interpretations that are issued but not effective as at 30 June 2020:**

Amendments to TFRS 10 and TAS 28: Sale or Contribution of Assets between an Investor and its Associate or Joint Venture (Amendments); In December 2017, POA postponed the effective date of this amendment indefinitely pending the outcome of its research project on the equity method of accounting. the Group will wait until the final amendment to assess the impacts of the changes.

TFRS 17 will become effective for annual reporting periods beginning on or after 1 January 2023. The amendment will not have an impact on the financial position or performance of the Group.

Amendments to TAS 1, "Presentation of financial statements" amendment regarding the classification of liabilities; effective for annual reporting periods beginning on or after 1 January 2023. The Group is in the process of assessing the impact of the amendments on financial position or performance of the Group.

Amendments to TFRS 3 – Reference to the Conceptual Framework; The amendments issued to TFRS 3 which are effective for periods beginning on or after 1 January 2022 and must be applied prospectively. the Group is in the process of assessing the impact of the amendments on financial position or performance of the Group.

Amendments to TAS 16 – Proceeds before intended use; The amendments issued to TAS 16 which are effective for periods beginning on or after 1 January 2022. The Group is in the process of assessing the impact of the amendments on financial position or performance of the Group.

Amendments to TAS 37 – Onerous contracts – Costs of Fulfilling a Contract; The amendments issued to TAS 37 which are effective for periods beginning on or after 1 January 2022 The Group is in the process of assessing the impact of the amendments on financial position or performance of the Group.

The Group is in the process of assessing the impact of the standards, a amendments and interpretations on financial position or performance of the Group.

**Annual Improvements – 2018–2020 Cycle**

TFRS 1 First-time Adoption of International Financial Reporting Standards – Subsidiary as a first-time adopter: The amendment permits a subsidiary to measure cumulative translation differences using the amounts reported by the parent. The amendment is also applied to an associate or joint venture.

TFRS 9 Financial Instruments – Fees in the “10 per cent test” for derecognition of financial liabilities: The amendment clarifies the fees that an entity includes when assessing whether the terms of a new or modified financial liability are substantially different from the terms of the original financial liability.

TAS 41 Agriculture – Taxation in fair value measurements: The amendment removes the requirement in paragraph 22 of TAS 41 that entities exclude cash flows for taxation when measuring fair value of assets within the scope of TAS 41.

Improvements are effective for annual reporting periods beginning on or after 1 January 2022. Earlier application is permitted for all.

The Group is in the process of assessing the impact of the amendments and improvements on financial position or performance of the Group.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS  
ORIGINALLY ISSUED IN TURKISH  
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD  
ENDED 30 JUNE 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**2. BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)**

**2.3 Comparative Information and Restatement/Reclassification of Prior Period Consolidated Financial Statements**

In order to allow the determination of financial position and performance, the Group's consolidated financial statements are prepared in comparison with the previous period. In order to comply with the presentation of consolidated financial statements the current period when deemed necessary, comparative information is reclassified, and material differences are presented. The Group has made some reclassifications to prior period financials in order to conform to current period financial statements.

The Group has reclassified investments fund with financial asset characteristics from cash and cash equivalents to financial assets measured at fair value through profit or loss in the financial statements as of June 30, 2020. Such reclassification has been made due to unpredictability of the change in fair value and not being readily convertible into precise certain known amounts of cash at inception on individual investment fund level. The Group has made restatements to prior periods balance sheets and cash flow statements in order to confirm to current period financial statements. The effects of the restatement in the consolidated statement of financial position as of 31 December 2019 and in the interim condensed consolidated statements of cash flows for the six months period ended 30 June 2019 are as follows;

|                                                                         | <b>31 December 2019<br/>Restated</b>            | <b>Effects of<br/>Restatement</b> | <b>31 December 2019<br/>Previously<br/>Reported</b>            |
|-------------------------------------------------------------------------|-------------------------------------------------|-----------------------------------|----------------------------------------------------------------|
| <b>Condensed consolidated financial statements</b>                      |                                                 |                                   |                                                                |
| Cash and cash equivalents                                               | 2.027.599                                       | (3.053.379)                       | 5.080.978                                                      |
| Short term financial investments                                        | 3.057.459                                       | 3.053.379                         | 4.080                                                          |
|                                                                         |                                                 |                                   |                                                                |
|                                                                         | <b>1 January-<br/>30 June 2019<br/>Restated</b> | <b>Effects of<br/>Restatement</b> | <b>1 January-<br/>30 June 2019<br/>Previously<br/>Reported</b> |
| <b>Condensed consolidated cash flow</b>                                 |                                                 |                                   |                                                                |
| Net cash generated from operating activities                            | 211.473                                         | 117                               | 211.356                                                        |
| Net cash generated from investing activities                            | 790.212                                         | 571.289                           | 218.923                                                        |
| The effect of foreign exchange rate change on cash and cash equivalents | 90.985                                          | (277.940)                         | 368.925                                                        |
| Cash and cash equivalents at the beginning of the period                | 999.462                                         | (2.379.299)                       | 3.378.761                                                      |
| Cash and cash equivalents at the end of the period                      | 2.032.442                                       | (2.085.833)                       | 4.118.275                                                      |

The Group has accounted the fair value decreases below the cost of the financial assets, which are carried at fair value through other comprehensive income in accordance with TFRS 9, in the statement of income for the year ended December 31, 2019. In 2020, the Group has restated the fair value decreases and accounted in the statement of other comprehensive income as required by Turkish Financial Reporting Standards 9. Accordingly, TL 91.201 thousands, fair value decrease after tax, has been reclassified from net income for the year end of 2019 to Gains from Financial Assets Measured at Fair Value Through Other Comprehensive Income in the interim condensed consolidated statement of financial position as at December 31, 2019.

|                                                                                       | <b>31 December<br/>2019<br/>Restated</b> | <b>Effects of Restatement</b> | <b>31 December 2019<br/>Previously<br/>Reported</b> |
|---------------------------------------------------------------------------------------|------------------------------------------|-------------------------------|-----------------------------------------------------|
| <b>Condensed consolidated statement of financial position</b>                         |                                          |                               |                                                     |
| Net profit for the period                                                             | 996.503                                  | 91.201                        | 905.302                                             |
| Gains from Financial Assets Measured at Fair Value through Other Comprehensive Income | 422.738                                  | (91.201)                      | 513.939                                             |

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS  
ORIGINALLY ISSUED IN TURKISH  
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD  
ENDED 30 JUNE 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**2. BASIS OF PRESENTATION OF FINANCIAL STATEMENTS (Continued)**

**2.4 Significant Accounting Policies**

**Financial instruments**

Fair values of financial instruments that do not have an active market as of 30 June 2020; it is calculated by the Group by using discounted cash flow analysis. In the current period, discount rates of 9,3% (2019: 12%) for G-New and 11,3% (2019: 12%) and terminal value of 2% for Godiva Belgium (2019: 2%) and 2% (2019: 2%) for G-New are used. The 0,3% change in the discount rate used affects the fair value of G-New (2019: 0,3%) and Godiva Belgium by 8.307 thousand TL and 12.264 thousand TL respectively (2019: G New: 1.138 thousand TL and Godiva Belgium: 2.963 thousand TL).

**2.5 Significant Changes Regarding Current Period**

The necessary actions were taken by the Group management to minimize the possible effects of COVID-19, which affects the whole world, on the operations and financial position of the Group. Meanwhile, actions were taken by the Group to minimize the increase in investment expenditures, operational expenses and inventories, and the cash management strategy is considered to strengthen the liquidity position. The COVID-19 pandemic did not have a significant impact on the financial position or performance of the Group.

While the Group preparing the interim condensed consolidated financial statements dated June 30, 2020, the Group evaluated the possible effects of the COVID-19 pandemic on the consolidated financial statements and reviewed the estimates and assumptions used in the preparation of the interim condensed consolidated financial statements. In this context, possible impairments in the financial assets, inventories, tangible assets, goodwill and brands in the interim condensed consolidated financial statements of 30 June 2020 is analysed and the necessary changes is reflected in the consolidated financial statements.

**3. SEGMENTAL INFORMATION**

The Group's core business activities are manufacturing and marketing of biscuit, chocolate coated biscuit, wafer, cake and chocolate. The reports reviewed routinely by the decision makers of the Group comprise consolidated financial information of Ülker Bisküvi Sanayi A.Ş. and its subsidiaries. The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the board of directors that makes strategic decisions. The Group management has determined the operating segments based on the reports reviewed by the board of directors that are used to make strategic decisions. The board of directors review segmental analysis on gross profit and operational profit.

The Group follows its operations with domestic (local operations of Turkish companies in Turkey) and international basis in accordance with TFRS 8. The information for 1 January – 30 June 2020 and 1 January – 30 June 2019.

|                      | <b>Domestic</b> | <b>Foreign</b> | <b>1 January -<br/>30 June 2020</b> |
|----------------------|-----------------|----------------|-------------------------------------|
| Revenue              | 2.736.219       | 1.784.548      | 4.520.767                           |
| Gross Profit         | 626.263         | 677.153        | 1.303.416                           |
| Operating Profit (*) | 376.086         | 329.075        | 705.161                             |
| EBITDA (**)          | 417.938         | 377.008        | 794.946                             |
| EBITDA/Revenue       | 15,3%           | 21,1%          | 17,6%                               |
| Capital Expenditures | 32.103          | 14.623         | 46.726                              |
|                      | <b>Domestic</b> | <b>Foreign</b> | <b>1 January -<br/>30 June 2019</b> |
| Revenue              | 2.320.967       | 1.441.891      | 3.762.858                           |
| Gross Profit         | 509.664         | 537.674        | 1.047.338                           |
| Operating Profit (*) | 307.019         | 256.995        | 564.014                             |
| EBITDA (**)          | 348.102         | 300.676        | 648.778                             |
| EBITDA/Revenue       | 15,0%           | 20,9%          | 17,2%                               |
| Capital Expenditures | 97.850          | 20.035         | 117.885                             |

(\*) Operating profit before other income/expense.

(\*\*) EBITDA (Earnings before interest, tax, depreciation and amortization) is calculated by adding back the non-cash expenses of depreciation and amortization to a Group's operating income. EBITDA isn't a measure of performance identified in TFRS, thus it may not be a tool for comparison for firms.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS  
 ORIGINALLY ISSUED IN TURKISH  
 ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES  
 NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD  
 ENDED 30 JUNE 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**4. CASH AND CASH EQUIVALENTS**

|                      | <b>30 June 2020</b> | <b>31 December 2019</b> |
|----------------------|---------------------|-------------------------|
| Cash on hand         | 1.420               | 180                     |
| Demand deposits      | 505.370             | 344.705                 |
| Time deposits        | 2.462.324           | 1.689.735               |
| Impairment provision | (13.114)            | (7.021)                 |
|                      | <b>2.956.000</b>    | <b>2.027.599</b>        |

Details of time deposits are shown below:

| <b>Currency Type</b> | <b>Annual Weighted<br/>Average<br/>Effective Interest Rate</b> | <b>Maturity</b> | <b>30 June 2020</b> |
|----------------------|----------------------------------------------------------------|-----------------|---------------------|
| TL                   | 7,70%                                                          | July 2020       | 350.071             |
| EUR                  | 0,71%                                                          | July 2020       | 632.101             |
| USD                  | 1,25%                                                          | July 2020       | 1.424.931           |
| EGP                  | 8,67%                                                          | July 2020       | 51.589              |
| KZT                  | 10,00%                                                         | July 2020       | 3.632               |
|                      |                                                                |                 | <b>2.462.324</b>    |

| <b>Currency Type</b> | <b>Annual Weighted<br/>Average<br/>Effective Interest Rate</b> | <b>Maturity</b> | <b>31 December 2019</b> |
|----------------------|----------------------------------------------------------------|-----------------|-------------------------|
| TL                   | 11,08%                                                         | January 2020    | 221.828                 |
| EUR                  | 0,05%                                                          | January 2020    | 20.879                  |
| USD                  | 2,69%                                                          | January 2020    | 1.396.246               |
| GBP                  | 0,15%                                                          | January 2020    | 5.217                   |
| EGP                  | 11,01%                                                         | January 2020    | 21.925                  |
| KZT                  | 10,00%                                                         | January 2020    | 23.640                  |
|                      |                                                                |                 | <b>1.689.735</b>        |

**5. FINANCIAL INVESTMENTS**

**Short Term Financial Investments:**

Financial Assets Measured at Fair Value through  
Profit or Loss (\*)

| <b>30 June 2020</b> | <b>31 December 2019</b> |
|---------------------|-------------------------|
| 3.605.728           | 3.057.459               |
| <b>3.605.728</b>    | <b>3.057.459</b>        |

**Long Term Financial Investments:**

Financial Assets Measured at Fair Value through Other  
Comprehensive Income (\*\*)

| <b>30 June 2020</b> | <b>31 December 2019</b> |
|---------------------|-------------------------|
| 1.108.045           | 946.029                 |
| <b>1.108.045</b>    | <b>946.029</b>          |

**Long Term**

**Financial Assets Measured at Fair Value through  
Other Comprehensive Income**

|                     | <b>30 June 2020</b> | <b>31 December 2019</b> |
|---------------------|---------------------|-------------------------|
| G New, Inc          | 331.418             | 312.171                 |
| Godiva Belgium BVBA | 776.427             | 633.658                 |
| Other               | 200                 | 200                     |
|                     | <b>1.108.045</b>    | <b>946.029</b>          |

(\*) TL 3.600.667 thousands of short-term financial investments consist of liquid mutual funds with a maturity of less than 3 months (31 December 2019: TL 3.053.379 thousands).

(\*\*) Equity investments that the Group does not have a significant influence are classified as financial assets measured at fair value through other comprehensive income as at 30 June 2020 amounting to TL 573.766 thousand have been presented under shareholder's equity.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS  
 ORIGINALLY ISSUED IN TURKISH  
 ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES  
 NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD  
 ENDED 30 JUNE 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**6. FINANCIAL LIABILITIES**

|                                             | <b>30 June 2020</b> | <b>31 December 2019</b> |
|---------------------------------------------|---------------------|-------------------------|
| Short term liabilities                      | 115.995             | 150.764                 |
| Short term portion of long-term liabilities | 3.364.123           | 5.088.239               |
| Long term liabilities                       | 3.753.105           | 701.318                 |
|                                             | <b>7.233.223</b>    | <b>5.940.321</b>        |

  

| <b><u>Short Term Liabilities</u></b>            | <b>30 June 2020</b> | <b>31 December 2019</b> |
|-------------------------------------------------|---------------------|-------------------------|
| Bank loans                                      | 13.872              | 66.437                  |
| Non-trade payables to related parties (Note 23) | 102.123             | 84.327                  |
|                                                 | <b>115.995</b>      | <b>150.764</b>          |

  

| <b><u>Short Term Portion of Long-Term Liabilities</u></b> | <b>30 June 2020</b> | <b>31 December 2019</b> |
|-----------------------------------------------------------|---------------------|-------------------------|
| Bank loans                                                | 3.347.150           | 5.074.414               |
| Lease liabilities                                         | 16.973              | 13.825                  |
|                                                           | <b>3.364.123</b>    | <b>5.088.239</b>        |

  

| <b><u>Long Term Liabilities</u></b> | <b>30 June 2020</b> | <b>31 December 2019</b> |
|-------------------------------------|---------------------|-------------------------|
| Bank loans                          | 3.712.722           | 652.490                 |
| Lease liabilities                   | 40.383              | 48.828                  |
|                                     | <b>3.753.105</b>    | <b>701.318</b>          |

The group has used a syndication loan in 27 November 2017. Details of Group's syndication loans are as follows: Syndication loan consists of two credit tranches which are USD 111.498.684 and EUR 290.559.069. 15 international banks joined to the syndication. Effective interest rate for both credit tranches are Euribor + 3,00 % for EUR, Libor + 2,90 % for USD and the maturity date is 27 November 2020. Principal payments of the loans are repaid at maturity with semi-annual interest payments.

In addition to syndication loan used in November 2017, the Group has used a new syndication loan consists of two credit tranches which are USD 110.000.000 and EUR 243.938.528 in 20 April 2020. 7 international banks joined to the syndication. Effective interest rate for both credit tranches are Euribor + 2,95% for EUR, Libor + 3,10% for USD and the maturity date is 20 April 2023. In addition to syndication loan, the Group has used EBRD credit which is EUR 75.000.000. Effective interest rate for EBRD credit tranche is Euribor + 2,95% for EUR and the maturity date are 20 April 2023. Principal payments of the loans are repaid at maturity with semi-annual interest payments.

- a) **Leverage:** The ratio of the consolidated net debt at balance sheet date to the last twelve months consolidated EBITDA (Earnings before interest, tax, depreciation and amortization) in the valid period should not be over 3,50 to 1.
- b) **Interest Coverage:** Consolidated interest coverage ratio of the Group should be at least 2 to 1.

In the current period ended June 30, 2020, the consolidated financial statements of the Group comply with the covenants of the syndication loan agreement.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS  
 ORIGINALLY ISSUED IN TURKISH  
 ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES  
 NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD  
 ENDED 30 JUNE 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**6. FINANCIAL LIABILITIES (Continued)**

**Liabilities:**

**30 June 2020**

| <u>Currency Type</u> | <u>Maturity</u>           | <u>Effective Weighted</u> | <u>Short Term</u> | <u>Long Term</u> |
|----------------------|---------------------------|---------------------------|-------------------|------------------|
|                      |                           | <u>Average Interest</u>   |                   |                  |
|                      |                           | <u>Rate (%)</u>           |                   |                  |
| TL                   | July 2020-July 2023       | 15,73%                    | 119.096           | 40.384           |
| EUR                  | October 2020-May 2023     | 2,99%                     | 2.521.675         | 2.727.554        |
| USD                  | October 2020-April 2023   | 4,52%                     | 797.306           | 717.561          |
| KZT                  | October 2020-January 2026 | 10,00%                    | 36.444            | 267.606          |
| SAR                  | July 2020                 | 4,76%                     | 5.597             | -                |
|                      |                           |                           | <b>3.480.118</b>  | <b>3.753.105</b> |

**31 December 2019**

| <u>Currency Type</u> | <u>Maturity</u>            | <u>Effective Weighted</u> | <u>Short Term</u> | <u>Long Term</u> |
|----------------------|----------------------------|---------------------------|-------------------|------------------|
|                      |                            | <u>Average Interest</u>   |                   |                  |
|                      |                            | <u>Rate (%)</u>           |                   |                  |
| TL                   | January 2020-April 2023    | 18,72%                    | 98.153            | 48.828           |
| EUR                  | February 2020-May 2023     | 3,01%                     | 3.585.375         | 379.467          |
| USD                  | January 2020-November 2020 | 4,92%                     | 1.539.388         | -                |
| KZT                  | January 2020-January 2026  | 10,00%                    | 6.379             | 273.023          |
| SAR                  | January 2020-July 2020     | 4,00%                     | 9.708             | -                |
|                      |                            |                           | <b>5.239.003</b>  | <b>701.318</b>   |

The maturity detail of the bank loans is as follows:

|                             | <b><u>30 June 2020</u></b> | <b><u>31 December 2019</u></b> |
|-----------------------------|----------------------------|--------------------------------|
| to be paid within 1 year    | 3.463.145                  | 5.225.178                      |
| to be paid within 1-2 years | 336.637                    | 273.085                        |
| to be paid within 2-3 years | 3.206.839                  | 215.508                        |
| to be paid within 3-4 years | 70.653                     | 98.892                         |
| to be paid within 4-5 years | 56.338                     | 52.004                         |
| Above 5 years               | 42.255                     | 13.001                         |
|                             | <b>7.175.867</b>           | <b>5.877.668</b>               |

**Short Term Financial Lease Liabilities**

|                                       | <b><u>30 June 2020</u></b> | <b><u>31 December 2019</u></b> |
|---------------------------------------|----------------------------|--------------------------------|
| Lease liabilities                     | 30.433                     | 29.282                         |
| Future finance charges on leasing (-) | (13.460)                   | (15.457)                       |
|                                       | <b>16.973</b>              | <b>13.825</b>                  |

**Long Term Financial Lease Liabilities**

|                                       | <b><u>30 June 2020</u></b> | <b><u>31 December 2019</u></b> |
|---------------------------------------|----------------------------|--------------------------------|
| Lease liabilities                     | 51.253                     | 65.895                         |
| Future finance charges on leasing (-) | (10.870)                   | (17.067)                       |
|                                       | <b>40.383</b>              | <b>48.828</b>                  |

The maturity detail of the lease liabilities is as follows:

|                             | <b><u>30 June 2020</u></b> | <b><u>31 December 2019</u></b> |
|-----------------------------|----------------------------|--------------------------------|
| to be paid within 1 year    | 16.973                     | 13.825                         |
| to be paid within 1-2 years | 20.725                     | 18.108                         |
| to be paid within 2-3 years | 19.658                     | 23.720                         |
| to be paid within 3-4 years | -                          | 7.000                          |
|                             | <b>57.356</b>              | <b>62.653</b>                  |

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS  
 ORIGINALLY ISSUED IN TURKISH  
 ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES  
 NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD  
 ENDED 30 JUNE 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**7. TRADE RECEIVABLES AND PAYABLES**

|                                            | <b>30 June 2020</b> | <b>31 December 2019</b> |
|--------------------------------------------|---------------------|-------------------------|
| <b>Short Term Due from Related Parties</b> |                     |                         |
| Due from related parties (Note 23)         | 2.296.692           | 2.106.741               |
|                                            | <b>2.296.692</b>    | <b>2.106.741</b>        |
| <b>Other Trade Receivables</b>             |                     |                         |
| Trade receivables                          | 291.277             | 269.750                 |
| Notes receivables                          | 1.369               | 84                      |
| Provision for doubtful receivables         | (12.096)            | (10.773)                |
|                                            | <b>280.550</b>      | <b>259.061</b>          |
| <b>Total Short-Term Trade Receivables</b>  | <b>2.577.242</b>    | <b>2.365.802</b>        |

The movement of the allowance for doubtful receivables as of 30 June 2020 and 2019 is as follows:

|                                  | <b>1 January - 30 June<br/>2020</b> | <b>1 January - 30 June<br/>2019</b> |
|----------------------------------|-------------------------------------|-------------------------------------|
| Opening balance                  | (10.773)                            | (19.351)                            |
| Current period expense           | (821)                               | (1.268)                             |
| Cancelled provision              | 331                                 | 2.472                               |
| Currency translation differences | (976)                               | (879)                               |
| Collection                       | 143                                 | 367                                 |
| <b>Ending Balance</b>            | <b>(12.096)</b>                     | <b>(18.659)</b>                     |

|                                  | <b>30 June 2020</b> | <b>31 December 2019</b> |
|----------------------------------|---------------------|-------------------------|
| <b>Short Term Trade Payables</b> |                     |                         |
| Due to related parties (Note 23) | 398.629             | 607.365                 |
| Trade payables                   | 555.870             | 617.233                 |
|                                  | <b>954.499</b>      | <b>1.224.598</b>        |

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS**  
**ORIGINALLY ISSUED IN TURKISH**  
**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**  
**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD**  
**ENDED 30 JUNE 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**8. OTHER RECEIVABLES AND PAYABLES**

|                                     | <b>30 June 2020</b> | <b>31 December 2019</b> |
|-------------------------------------|---------------------|-------------------------|
| <b>Other Receivables</b>            |                     |                         |
| Due from related parties (Note 23)  | 115.748             | 115.619                 |
| Short term other receivables        | 43.178              | 37.283                  |
|                                     | <b>158.926</b>      | <b>152.902</b>          |
|                                     | <b>30 June 2020</b> | <b>31 December 2019</b> |
| <b>Other Short-Term Receivables</b> |                     |                         |
| VAT receivables                     | 17.451              | 17.229                  |
| Deposits and guarantees given       | 24.017              | 18.277                  |
| Receivables from personnel          | 972                 | 1.568                   |
| Other                               | 738                 | 209                     |
|                                     | <b>43.178</b>       | <b>37.283</b>           |
|                                     | <b>30 June 2020</b> | <b>31 December 2019</b> |
| <b>Other Long-Term Receivables</b>  |                     |                         |
| Deposits and guarantees given       | 344                 | 460                     |
|                                     | <b>344</b>          | <b>460</b>              |
|                                     | <b>30 June 2020</b> | <b>31 December 2019</b> |
| <b>Other Payables</b>               |                     |                         |
| Due from related parties (Note 23)  | 1.523               | 113                     |
| Other short-term payables           | 3.161               | 4.994                   |
|                                     | <b>4.684</b>        | <b>5.107</b>            |
|                                     | <b>30 June 2020</b> | <b>31 December 2019</b> |
| <b>Other Short-Term Payables</b>    |                     |                         |
| Deposits and guarantees received    | 124                 | 124                     |
| Other short-term payables           | 3.037               | 4.870                   |
|                                     | <b>3.161</b>        | <b>4.994</b>            |

**9. DERIVATIVE INSTRUMENTS**

As date of 20 April 2017, the Group received syndication loans which are USD 136.000.000 and EUR 225.144.922 respectively. Principal payments of the loans are repaid at maturity with semi-annual interest payments in parallel with repayment schedule, the Group entered into a cross currency fixed interest rate swap contracts amounting to USD 116.000.000 and EUR 30.000.000, respectively to manage its exposure to interest rate and foreign currency fluctuations. The cross currency fixed interest rate swap contracts were closed as of 20 April 2020.

The Group entered into fixed interest rate swap contracts amounting to USD 33.000.000 in order to hedge the interest rate risk in line with the repayment schedule of the USD 110,000,000 tranches of 3-year term and floating rate syndication loan received as date of 20 April 2020.

Derivative instruments as of 30 June 2020 and 31 December 2019 are as follows:

|                                              | <b>30 June 2020</b>    |                   | <b>31 December 2019</b> |                   |
|----------------------------------------------|------------------------|-------------------|-------------------------|-------------------|
|                                              | <b>Contract Amount</b> | <b>Fair Value</b> | <b>Contract Amount</b>  | <b>Fair Value</b> |
| <b>Derivative instruments held for hedge</b> |                        |                   |                         |                   |
| Cross Currency Fixed Interest Rate Swap      | -                      | -                 | 528.132                 | 358.919           |
| Fixed Interest Rate Swap                     | 225.793                | (781)             | -                       | -                 |
| <b>Total Asset / (Liabilities)</b>           | <b>225.793</b>         | <b>(781)</b>      | <b>528.132</b>          | <b>358.919</b>    |

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS**  
**ORIGINALLY ISSUED IN TURKISH**  
**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**  
**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD**  
**ENDED 30 JUNE 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**10. INVENTORIES**

Details of inventory are as follows;

|                                           | <b>30 June 2020</b> | <b>31 December 2019</b> |
|-------------------------------------------|---------------------|-------------------------|
| Raw materials                             | 367.846             | 231.633                 |
| Work in progress                          | 38.969              | 24.430                  |
| Finished goods                            | 314.070             | 272.475                 |
| Trade goods                               | 47.070              | 34.347                  |
| Other inventories                         | 60.105              | 47.843                  |
| Allowance for impairment on inventory (-) | (23.357)            | (18.030)                |
|                                           | <b>804.703</b>      | <b>592.698</b>          |

Inventory is presented on cost value and allowance for impairment is booked for inventory valuing lower than cost.

The movement of allowance for impairment on inventory for the periods ended on 30 June 2020 and 2019 are below:

|                                  | <b>1 January-<br/>30 June 2020</b> | <b>1 January-<br/>30 June 2019</b> |
|----------------------------------|------------------------------------|------------------------------------|
| Opening balance                  | (18.030)                           | (11.829)                           |
| Charge for the period            | (5.567)                            | (9.158)                            |
| Reversal of provision            | 1.170                              | 1.643                              |
| Currency translation differences | (930)                              | (432)                              |
| Closing balance                  | <b>(23.357)</b>                    | <b>(19.776)</b>                    |

**11. INVESTMENT PROPERTIES**

|                        | <b>1 January-<br/>30 June 2020</b> | <b>1 January-<br/>30 June 2019</b> |
|------------------------|------------------------------------|------------------------------------|
| Opening balance        | 21.155                             | 21.036                             |
| <b>Closing balance</b> | <b>21.155</b>                      | <b>21.036</b>                      |

The fair value of the Group's investment properties at 30 June 2020 has been determined on the basis of a valuation study carried out as of 31 December 2019, by an independent valuation company, namely, NOVA Taşınmaz Değerleme ve Danışmanlık A.Ş, which is not related to the Group and is one of the accredited independent valuers by Capital Markets Board of Turkey and has appropriate qualifications and recent experience in the valuation of properties in the relevant locations. The valuation, which conforms to International Valuation Standards, based on market evidence of transaction prices for similar properties.

The rent income earned by the Group from its investment properties amounting to TL 720 thousand (30 June 2019: TL 758 thousand) as of 30 June 2020. Direct operating expenses arising from the investment properties in the current period amounting to TL 69 thousand. (30 June 2019: TL 57 thousand).

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**  
**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2020

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise stated)

**12. TANGIBLE ASSETS**

Movement of tangible assets between 1 January 2020 and 30 June 2020 is as follows:

| <b>Cost</b>                     | <b>1 January 2020</b> | <b>Addition</b>                  | <b>Disposal</b> | <b>Transfer</b> | <b>Currency<br/>Translation<br/>Differences</b> | <b>30 June 2020</b> |
|---------------------------------|-----------------------|----------------------------------|-----------------|-----------------|-------------------------------------------------|---------------------|
| Land                            | 720.030               | -                                | -               | -               | 3.701                                           | 723.731             |
| Buildings                       | 820.437               | 6.688                            | -               | 1.027           | 29.872                                          | 858.024             |
| Machinery, plant and equipment  | 2.197.143             | 11.415                           | (3.135)         | 26.017          | 108.918                                         | 2.340.358           |
| Vehicles                        | 12.656                | -                                | (25)            | -               | 1.042                                           | 13.673              |
| Furniture and fixture           | 112.036               | 3.073                            | (460)           | 3.384           | 6.203                                           | 124.236             |
| Leasehold improvements          | 41.518                | 79                               | (11)            | (12)            | 41                                              | 41.615              |
| Other tangible assets           | 975                   | -                                | -               | -               | 148                                             | 1.123               |
| Construction in progress        | 63.648                | 23.372                           | (824)           | (30.416)        | 2.794                                           | 58.574              |
|                                 | <b>3.968.443</b>      | <b>44.627</b>                    | <b>(4.455)</b>  | <b>-</b>        | <b>152.719</b>                                  | <b>4.161.334</b>    |
| <b>Accumulated Depreciation</b> | <b>1 January 2020</b> | <b>Charge for the<br/>period</b> | <b>Disposal</b> | <b>Transfer</b> | <b>Currency<br/>Translation<br/>Differences</b> | <b>30 June 2020</b> |
| Buildings                       | (377.766)             | (11.846)                         | -               | -               | (12.530)                                        | (402.142)           |
| Machinery, plant and equipment  | (1.095.425)           | (69.532)                         | 2.490           | -               | (54.589)                                        | (1.217.056)         |
| Vehicles                        | (9.143)               | (710)                            | 25              | -               | (906)                                           | (10.734)            |
| Furniture and fixture           | (78.955)              | (4.559)                          | 437             | -               | (4.591)                                         | (87.668)            |
| Leasehold improvements          | (22.893)              | (1.947)                          | 3               | -               | (17)                                            | (24.854)            |
| Other tangible assets           | (1.084)               | (63)                             | -               | -               | 362                                             | (785)               |
|                                 | <b>(1.585.266)</b>    | <b>(88.657)</b>                  | <b>2.955</b>    | <b>-</b>        | <b>(72.271)</b>                                 | <b>(1.743.239)</b>  |
| <b>Net Book Value</b>           | <b>2.383.177</b>      |                                  |                 |                 |                                                 | <b>2.418.095</b>    |

From depreciation and amortization expenses, TL 84.563 thousand (30 June 2019: TL 77.551 thousand) is included in cost of goods sold, TL 178 thousand (30 June 2019: TL 205 thousand) is included in research and development expenses, TL 2.162 thousand (30 June 2019: TL 1.596 thousand) is included in marketing and selling expenses, TL 2.882 thousand (30 June 2019: TL 5.412 thousand) is included in general and administrative expenses. There is not any mortgage or collateral on tangible assets.

CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH  
 ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES  
 NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**12. TANGIBLE ASSETS (Continued)**

Movement of tangible assets between 1 January 2019 and 30 June 2019 is as follows:

| <b>Cost</b>                    | <b>1 January 2019</b> | <b>Addition</b> | <b>Disposal</b> | <b>Transfer</b> | <b>Currency<br/>Translation<br/>Differences</b> | <b>30 June 2019</b> |
|--------------------------------|-----------------------|-----------------|-----------------|-----------------|-------------------------------------------------|---------------------|
| Land                           | 714.750               | -               | -               | -               | 3.559                                           | 718.309             |
| Buildings                      | 698.303               | 72.472          | -               | 1.173           | 20.238                                          | 792.186             |
| Machinery, plant and equipment | 2.038.567             | 6.856           | (13.644)        | 6.188           | 70.242                                          | 2.108.209           |
| Vehicles                       | 11.697                | -               | (328)           | -               | 706                                             | 12.075              |
| Furniture and fixture          | 95.810                | 3.211           | (348)           | 44              | 3.190                                           | 101.907             |
| Leasehold improvements         | 41.326                | 417             | -               | -               | 23                                              | 41.766              |
| Other tangible assets          | 798                   | -               | -               | -               | 226                                             | 1.024               |
| Construction in progress       | 44.470                | 33.259          | -               | (7.405)         | 3.422                                           | 73.746              |
|                                | <b>3.645.721</b>      | <b>116.215</b>  | <b>(14.320)</b> | <b>-</b>        | <b>101.606</b>                                  | <b>3.849.222</b>    |

  

| <b>Accumulated Depreciation</b> | <b>1 January 2019</b> | <b>Charge for<br/>period</b> | <b>Disposal</b> | <b>Transfer</b> | <b>Currency<br/>Translation<br/>Differences</b> | <b>30 June 2019</b> |
|---------------------------------|-----------------------|------------------------------|-----------------|-----------------|-------------------------------------------------|---------------------|
| Buildings                       | (346.062)             | (10.651)                     | -               | -               | (7.632)                                         | (364.345)           |
| Machinery, plant and equipment  | (925.608)             | (64.844)                     | 6.063           | -               | (30.211)                                        | (1.014.600)         |
| Vehicles                        | (7.054)               | (698)                        | 153             | -               | (504)                                           | (8.103)             |
| Furniture and fixture           | (70.149)              | (3.914)                      | 134             | -               | (2.203)                                         | (76.132)            |
| Leasehold improvements          | (19.545)              | (2.000)                      | -               | -               | (6)                                             | (21.551)            |
| Other tangible assets           | (937)                 | (41)                         | -               | -               | (46)                                            | (1.024)             |
|                                 | <b>(1.369.355)</b>    | <b>(82.148)</b>              | <b>6.350</b>    | <b>-</b>        | <b>(40.602)</b>                                 | <b>(1.485.755)</b>  |

  

|                       |                  |  |  |  |  |                  |
|-----------------------|------------------|--|--|--|--|------------------|
| <b>Net Book Value</b> | <b>2.276.366</b> |  |  |  |  | <b>2.363.467</b> |
|-----------------------|------------------|--|--|--|--|------------------|

There is no fixed asset acquired through financial leasing as of 30 June 2020 (30 June 2019: TL 70.000 Thousand). There is not any mortgage or collateral on tangible assets (31 December 2019: None).

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS  
ORIGINALLY ISSUED IN TURKISH  
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM  
PERIOD ENDED 30 JUNE 2020**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise stated)

**12. TANGIBLE ASSETS (Continued)**

The estimated useful lives of tangible assets are as follow:

|                                | Useful Life        |
|--------------------------------|--------------------|
| Buildings                      | 25 – 50 years      |
| Land improvements              | 10 – 50 years      |
| Machinery, plant and equipment | 4 – 20 years       |
| Vehicles                       | 4 – 10 years       |
| Other tangible assets          | 4 – 10 years       |
| Furniture and fixtures         | 3 – 10 years       |
| Leasehold improvements         | During rent period |

The Group decided to apply revaluation model to land and buildings in accordance with TMS 16. Land and buildings were revalued with “compare with similar” technique on 15 January 2018. The revaluation was performed by Nova Taşınmaz Değerleme ve Danışmanlık A.Ş. authorized by Capital Markets Board. Properties were accounted on 31 December 2017 financial statements based on their fair values. The frequency of revaluations is related with the changes on the market values of the properties. If there is material change at the fair value, revaluation is performed. If not, properties are only subject to periodical revaluation. The Group has assessed that there is no significant change in the fair value of land and buildings in the current period.

**13. GOODWILL**

|                                 | 30 June 2020   | 30 June 2019   |
|---------------------------------|----------------|----------------|
| 1 January                       | 388.047        | 331.975        |
| Currency translation difference | 32.520         | 31.571         |
| Closing Balance                 | <b>420.567</b> | <b>363.546</b> |

Goodwill details are as follow:

| Company      | 30 June 2020   | 31 December 2019 |
|--------------|----------------|------------------|
| UI Mena B.V. | 404.554        | 373.272          |
| IBC          | 16.013         | 14.775           |
|              | <b>420.567</b> | <b>388.047</b>   |

**UI Mena B.V.**

Yıldız Holding A.Ş. acquired United Biscuit Group as of 3 November 2014. Goodwill accounted at Yıldız Holding’s financial statement related with UI MENA operations is accounted to these financial statement by restating prior years.

**International Biscuits Company**

Yıldız Holding A.Ş. acquired United Biscuit Group as of 3 November 2014. Goodwill accounted at Yıldız Holding’s financial statement related with IBC acquisition is accounted to these financial statement by restating prior years.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS  
ORIGINALLY ISSUED IN TURKISH  
ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM  
PERIOD ENDED 30 JUNE 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**14. INTANGIBLE ASSETS**

Movements of intangible assets between 1 January 2020 - 30 June 2020 are as follows:

| <b>Cost</b>                     | <b>1 January 2020</b> | <b>Addition</b>              | <b>Currency Translation Differences</b> | <b>30 June 2020</b> |
|---------------------------------|-----------------------|------------------------------|-----------------------------------------|---------------------|
| Rights (*)                      | 299.979               | 1.525                        | 41.563                                  | 343.067             |
| Other intangible assets         | 5.988                 | 574                          | 490                                     | 7.052               |
|                                 | <b>305.967</b>        | <b>2.099</b>                 | <b>42.053</b>                           | <b>350.119</b>      |
| <b>Accumulated Amortization</b> | <b>1 January 2020</b> | <b>Charge for the period</b> | <b>Currency Translation Differences</b> | <b>30 June 2020</b> |
| Rights                          | (11.130)              | (406)                        | (1.260)                                 | (12.796)            |
| Other intangible assets         | (2.649)               | (722)                        | (76)                                    | (3.447)             |
|                                 | <b>(13.779)</b>       | <b>(1.128)</b>               | <b>(1.336)</b>                          | <b>(16.243)</b>     |
| <b>Net Book Value</b>           | <b>292.188</b>        |                              |                                         | <b>333.876</b>      |

Movements of intangible assets between 1 January 2019 – 30 June 2019 are as follows:

| <b>Cost</b>                     | <b>1 January 2019</b> | <b>Addition</b>              | <b>Currency Translation Differences</b> | <b>30 June 2019</b> |
|---------------------------------|-----------------------|------------------------------|-----------------------------------------|---------------------|
| Rights (*)                      | 263.730               | 1.494                        | 24.976                                  | 290.200             |
| Other intangible assets         | 3.251                 | 176                          | -                                       | 3.427               |
|                                 | <b>266.981</b>        | <b>1.670</b>                 | <b>24.976</b>                           | <b>293.627</b>      |
| <b>Accumulated Amortization</b> | <b>1 January 2019</b> | <b>Charge for the period</b> | <b>Currency Translation Differences</b> | <b>30 June 2019</b> |
| Rights                          | (6.382)               | (2.372)                      | (652)                                   | (9.406)             |
| Other intangible assets         | (2.841)               | (244)                        | -                                       | (3.085)             |
|                                 | <b>(9.223)</b>        | <b>(2.616)</b>               | <b>(652)</b>                            | <b>(12.491)</b>     |
| <b>Net Book Value</b>           | <b>257.758</b>        |                              |                                         | <b>281.136</b>      |

(\*) As of 30 June 2020 Rights contain reacquired rights related with Saudi distribution agreements of Groups products in Saudi Arabia amounting to TL 272.238 thousand (30 June 2019: TL 228.984 thousand), the remaining amount of TL 50.569 thousand (30 June 2019: TL 43.713 thousand) contains the rights of Rana brand. Reacquired rights are not subject to depreciation and has indefinite useful life. Impairment test is applied every year of when there is any indicator that impairment may occur.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**  
**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**14. INTANGIBLE ASSETS (Continued)**

The intangible assets are amortized on a straight-line basis over their estimated useful lives.

|                         | Useful Life               |
|-------------------------|---------------------------|
| Rights                  | 2 years - Indefinite life |
| Other intangible assets | 2 - 12 years              |
| Brand                   | Indefinite life           |

**15. OTHER PROVISIONS, CONTINGENT ASSETS AND LIABILITIES**

**Guarantees Given**

(Balances denominated in foreign currencies have been presented in their original currencies)

|                                                                                                    | 30 June 2020   |               |                | 31 December 2019 |               |                |
|----------------------------------------------------------------------------------------------------|----------------|---------------|----------------|------------------|---------------|----------------|
|                                                                                                    | TL             | USD           | EUR            | TL               | USD           | EUR            |
| A) CPM's given in the name of own legal identity (*)                                               | 201.266        | 25.608        | -              | 201.279          | 26.273        | -              |
| B) CPM's given on behalf of the fully consolidated companies                                       | -              | -             | 87.922         | -                | -             | 87.922         |
| C) CPM's given on behalf of third parties for ordinary course of business (**)                     | -              | -             | 97.950         | -                | -             | 97.270         |
| D) Total amount of other CPM's given                                                               |                |               |                |                  |               |                |
| i. Total amount of CPM's given on behalf of the majority shareholder (***)                         | -              | -             | -              | -                | -             | -              |
| ii. Total amount of CPM's given on behalf of the group companies which are not in scope of B and C | -              | -             | -              | -                | -             | -              |
| iii. Total amount of CPM's given on behalf of third parties which are not in scope of C            | -              | -             | -              | -                | -             | -              |
| <b>Total</b>                                                                                       | <b>201.266</b> | <b>25.608</b> | <b>185.872</b> | <b>201.279</b>   | <b>26.273</b> | <b>185.192</b> |

(\*) Non-cash risk amounting to TL 54,9 million and USD 6,1 million.

(\*\*) Includes the warranty given for the group's raw material supplier in relation to the raw material purchases to be made on behalf of the group.

(\*\*\*) The ratio of other collaterals, pledges and mortgages given by the group to the group's parent company's equity is zero as of 30 June 2020 (31 December 2019: zero).

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**  
**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**15. OTHER PROVISIONS, CONTINGENT ASSETS AND LIABILITIES (Continued)**

**Guarantees Given (Continued)**

The Company's ultimate parent company Yıldız Holding A.Ş. and some Yıldız Holding Group entities including Ülker Bisküvi's subsidiaries entered into syndicated loan agreement with some of the "creditors" of Yıldız Holding A.Ş. and Yıldız Holding Group entities.

The cash balance of Ülker Bisküvi's subsidiaries with an amount of TL 146,3 million and USD 19,5 million and non-cash bank guarantees amounting to TL 45,7 million and USD 6,1 million, were transferred to the level of Yıldız Holding A.Ş. with syndication as of 8 June 2018. The Company's total debt has not increased as a result of the syndicated loan. Related Ülker Bisküvi's subsidiaries became guarantors of Yıldız Holding A.Ş. as of the date of using the loan limited to their existing total bank loan risk exposure.

**16. REVENUE AND COST OF SALES**

**a) Sales**

The detail of operating income is as follows:

|                                 | <b>1 January -<br/>30 June<br/>2020</b> | <b>1 April -<br/>30 June<br/>2020</b> | <b>1 January -<br/>30 June<br/>2019</b> | <b>1 April -<br/>30 June<br/>2019</b> |
|---------------------------------|-----------------------------------------|---------------------------------------|-----------------------------------------|---------------------------------------|
| Domestic sales (*)              | 4.983.984                               | 2.284.289                             | 4.107.532                               | 1.934.010                             |
| Export sales                    | 880.002                                 | 482.561                               | 804.645                                 | 424.314                               |
| Sales returns and discounts (-) | (1.343.219)                             | (622.209)                             | (1.149.319)                             | (537.826)                             |
| <b>Revenue (net)</b>            | <b>4.520.767</b>                        | <b>2.144.641</b>                      | <b>3.762.858</b>                        | <b>1.820.498</b>                      |
| Cost of goods sold              | (3.099.930)                             | (1.464.401)                           | (2.634.390)                             | (1.269.330)                           |
| Cost of trade goods sold        | (117.421)                               | (93.105)                              | (81.130)                                | (42.002)                              |
| <b>Cost of sales</b>            | <b>(3.217.351)</b>                      | <b>(1.557.506)</b>                    | <b>(2.715.520)</b>                      | <b>(1.311.332)</b>                    |
| <b>Gross Profit</b>             | <b>1.303.416</b>                        | <b>587.135</b>                        | <b>1.047.338</b>                        | <b>509.166</b>                        |

(\*) Presents domestic sales in Turkey and in countries where abroad subsidiaries are located.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**  
**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**17. EXPENSES BY NATURE**

The detail of operating expenses is as follow:

|                                        | <b>1 January -<br/>30 June<br/>2020</b> | <b>1 April -<br/>30 June<br/>2020</b> | <b>1 January -<br/>30 June<br/>2019</b> | <b>1 April -<br/>30 June<br/>2019</b> |
|----------------------------------------|-----------------------------------------|---------------------------------------|-----------------------------------------|---------------------------------------|
| <b>General Administrative Expenses</b> |                                         |                                       |                                         |                                       |
| Personnel expenses                     | (58.547)                                | (30.616)                              | (47.075)                                | (26.773)                              |
| Operating expenses                     | (48.932)                                | (26.136)                              | (19.316)                                | (12.425)                              |
| Consultancy expenses                   | (10.356)                                | (4.168)                               | (7.089)                                 | (4.287)                               |
| Depreciation and amortization expenses | (2.882)                                 | (1.484)                               | (5.412)                                 | (2.788)                               |
| Other                                  | (6.907)                                 | (1.404)                               | (15.693)                                | (9.699)                               |
|                                        | <b>(127.624)</b>                        | <b>(63.808)</b>                       | <b>(94.585)</b>                         | <b>(55.972)</b>                       |
| <b>Marketing Expenses</b>              |                                         |                                       |                                         |                                       |
| Marketing operating expenses           | (353.226)                               | (133.485)                             | (283.542)                               | (119.360)                             |
| Personnel expenses                     | (75.024)                                | (40.591)                              | (68.029)                                | (35.953)                              |
| Rent expenses                          | (9.888)                                 | (5.224)                               | (7.276)                                 | (5.966)                               |
| Depreciation and amortization expenses | (2.162)                                 | (1.182)                               | (1.596)                                 | (819)                                 |
| Other                                  | (19.155)                                | (3.342)                               | (19.207)                                | (10.748)                              |
|                                        | <b>(459.455)</b>                        | <b>(183.824)</b>                      | <b>(379.650)</b>                        | <b>(172.846)</b>                      |
| <b>Research Expenses</b>               |                                         |                                       |                                         |                                       |
| Personnel expenses                     | (7.143)                                 | (3.585)                               | (5.744)                                 | (3.490)                               |
| Materials used                         | (676)                                   | (452)                                 | (722)                                   | (421)                                 |
| Depreciation and amortization expenses | (178)                                   | (87)                                  | (205)                                   | (98)                                  |
| Other                                  | (3.179)                                 | (1.370)                               | (2.418)                                 | (1.244)                               |
|                                        | <b>(11.176)</b>                         | <b>(5.494)</b>                        | <b>(9.089)</b>                          | <b>(5.253)</b>                        |

**18. INCOME AND EXPENSES FROM INVESTMENT ACTIVITIES**

a) The detail of investment income is as follows:

|                                                         | <b>1 January -<br/>30 June<br/>2020</b> | <b>1 April -<br/>30 June<br/>2020</b> | <b>1 January -<br/>30 June<br/>2019</b> | <b>1 April -<br/>30 June<br/>2019</b> |
|---------------------------------------------------------|-----------------------------------------|---------------------------------------|-----------------------------------------|---------------------------------------|
| Foreign exchange gains                                  | 975.794                                 | 286.173                               | 433.369                                 | 102.290                               |
| Interest income                                         | 61.565                                  | 30.274                                | 123.358                                 | 70.601                                |
| Rent income                                             | 5.975                                   | 2.966                                 | 5.143                                   | 2.739                                 |
| Dividend Income                                         | 64                                      | 64                                    | 83                                      | 83                                    |
| Income on sales of tangible assets                      | 1.317                                   | -                                     | 2.048                                   | 1.730                                 |
| Fair value increase/(decrease) of financial investments | -                                       | -                                     | 132.530                                 | (34.234)                              |
|                                                         | <b>1.044.715</b>                        | <b>319.477</b>                        | <b>696.531</b>                          | <b>143.209</b>                        |

b) The detail of investment expenses is as follows:

|                                                         | <b>1 January -<br/>30 June<br/>2020</b> | <b>1 April -<br/>30 June<br/>2020</b> | <b>1 January -<br/>30 June<br/>2019</b> | <b>1 April -<br/>30 June<br/>2019</b> |
|---------------------------------------------------------|-----------------------------------------|---------------------------------------|-----------------------------------------|---------------------------------------|
| Fair value (decrease)/increase of financial investments | (137.078)                               | 431.608                               | -                                       | -                                     |
| Foreign exchange losses                                 | (105.946)                               | (2.381)                               | (6.936)                                 | 16.846                                |
| Loss on sales of tangible assets                        | (180)                                   | (103)                                 | (3.325)                                 | (2.052)                               |
|                                                         | <b>(243.204)</b>                        | <b>429.124</b>                        | <b>(10.261)</b>                         | <b>14.794</b>                         |

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**  
**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**19. FINANCIAL INCOME**

|                       | <b>1 January -<br/>30 June<br/>2020</b> | <b>1 April -<br/>30 June<br/>2020</b> | <b>1 January -<br/>30 June<br/>2019</b> | <b>1 April -<br/>30 June<br/>2019</b> |
|-----------------------|-----------------------------------------|---------------------------------------|-----------------------------------------|---------------------------------------|
| Foreign exchange gain | 188.641                                 | 181.536                               | 83.456                                  | 82.021                                |
| Other                 | 1.197                                   | 605                                   | 1.163                                   | 593                                   |
|                       | <b>189.838</b>                          | <b>182.141</b>                        | <b>84.619</b>                           | <b>82.614</b>                         |

**20. FINANCIAL EXPENSES**

|                                        | <b>1 January -<br/>30 June<br/>2020</b> | <b>1 April -<br/>30 June<br/>2020</b> | <b>1 January -<br/>30 June<br/>2019</b> | <b>1 April -<br/>30 June<br/>2019</b> |
|----------------------------------------|-----------------------------------------|---------------------------------------|-----------------------------------------|---------------------------------------|
| Foreign exchange losses from financing | (915.277)                               | (487.020)                             | (465.963)                               | (244.195)                             |
| Interest expenses                      | (185.961)                               | (92.461)                              | (199.575)                               | (115.462)                             |
| Other                                  | (19.208)                                | (12.572)                              | (14.765)                                | 1.734                                 |
|                                        | <b>(1.120.446)</b>                      | <b>(592.053)</b>                      | <b>(680.303)</b>                        | <b>(357.923)</b>                      |

**21. TAX ASSET AND LIABILITIES**

The Group accounts deferred tax assets and liabilities for temporary timing differences rooted from differences between legal financial statements and financial statements prepared in accordance with TFRS. The differences in question are caused generally by the fact that some profit and loss accounts come up in different periods in legal financial statements and financial statements prepared in accordance with TFRS. These differences are specified below.

Turkish tax legislation does not permit a parent company and its subsidiary to file a consolidated tax return. Therefore, deferred tax positions of the firms with deferred tax assets is netted against those with deferred tax liabilities and reflected on a separate-entity basis.

The Law was published in the Official Gazette on 5 December 2017. Accordingly, the corporate income tax rate for all companies will be increased from 20% to 22% for the years 2018, 2019 and 2020. Therefore, deferred tax assets and liabilities shall be measured in accordance with materiality at the tax rate of 22% that are expected to apply to these periods when the assets are realised or the liability is settled, based on the Law that have been enacted. For the periods 2021 and after, the reversals of temporary differences will be measured by 20%. At the same time, the exemption to be applied over the capital gains from the sales of the real estate taxpayers held for at least two years was reduced from 75% to 50% with the regulation published in the Official Gazette dated 5 December 2017.

The rate applied in the calculation of deferred tax assets and liabilities for entities in Turkey is 22% (2019: 22%, 2020: 22%), for entities in Saudi Arabia and Kazakhstan is 20% (2019: 20%), for entities in Egypt 22,5% (2019: 22,5%), and for entity in Kyrgyzstan 10% (2019: 10%), for entity in the United Arab Emirates is zero (2019: Zero).

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**  
**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**21 TAX ASSET AND LIABILITIES (Continued)**

Deferred tax bases:

|                                                                          | <b>30 June<br/>2020</b> | <b>31 December<br/>2019</b> | <b>30 June<br/>2020</b> | <b>31 December<br/>2019</b> |
|--------------------------------------------------------------------------|-------------------------|-----------------------------|-------------------------|-----------------------------|
| Indexation and useful life differences of tangible and intangible assets | -                       | -                           | 1.129.541               | 1.114.931                   |
| Investment properties valuation differences                              | -                       | -                           | 17.174                  | 17.174                      |
| Marketable securities valuation differences                              | -                       | -                           | 309.629                 | 89.868                      |
| Derivative instruments                                                   | (781)                   | -                           | -                       | 358.919                     |
| Profit margin elimination on inventories                                 | (4.968)                 | (12.891)                    | -                       | -                           |
| Rediscount on trade receivables/payables (net)                           | -                       | -                           | -                       | 487                         |
| Allowance of employee termination benefits                               | (137.941)               | (122.368)                   | -                       | -                           |
| Provision of doubtful receivables                                        | (17.802)                | (11.987)                    | -                       | -                           |
| Previous year losses                                                     | (81.314)                | (75.059)                    | -                       | -                           |
| Provision for lawsuits                                                   | (6.308)                 | (6.615)                     | -                       | -                           |
| Impairment on inventories                                                | (14.356)                | (14.986)                    | -                       | -                           |
| Provision for unused vacation                                            | (18.258)                | (16.148)                    | -                       | -                           |
| Other                                                                    | (86.697)                | (19.390)                    | 28.380                  | 17.601                      |
|                                                                          | <b>(368.425)</b>        | <b>(279.444)</b>            | <b>1.484.724</b>        | <b>1.598.980</b>            |
|                                                                          | <b>30 June<br/>2020</b> | <b>31 December<br/>2019</b> | <b>30 June<br/>2020</b> | <b>31 December<br/>2019</b> |
| Indexation and useful life differences of tangible and intangible assets | -                       | -                           | 154.613                 | 151.686                     |
| Investment properties valuation differences                              | -                       | -                           | 1.717                   | 1.717                       |
| Marketable securities valuation differences                              | -                       | -                           | 15.481                  | 4.493                       |
| Derivative instruments                                                   | (172)                   | -                           | -                       | 78.962                      |
| Profit elimination on inventories                                        | (1.093)                 | (2.836)                     | -                       | -                           |
| Rediscount on trade receivables/payables (net)                           | -                       | -                           | -                       | 107                         |
| Allowance of employee termination benefits                               | (27.588)                | (24.474)                    | -                       | -                           |
| Provision of doubtful receivables                                        | (3.916)                 | (2.637)                     | -                       | -                           |
| Previous year losses                                                     | (16.263)                | (15.012)                    | -                       | -                           |
| Provision for lawsuits                                                   | (1.388)                 | (1.455)                     | -                       | -                           |
| Impairment on inventories                                                | (3.158)                 | (3.297)                     | -                       | -                           |
| Investment incentive                                                     | (17.732)                | (21.115)                    | -                       | -                           |
| Provision for unused vacation                                            | (4.017)                 | (3.553)                     | -                       | -                           |
| Other                                                                    | (19.074)                | (4.263)                     | 6.244                   | 3.872                       |
|                                                                          | <b>(94.401)</b>         | <b>(78.642)</b>             | <b>178.055</b>          | <b>240.837</b>              |

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**  
**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**  
**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**21 TAX ASSET AND LIABILITIES (Continued)**

**Movement of Deferred Tax Liabilities:**

|                                                 | <b>1 January – 30 June<br/>2020</b> | <b>1 January - 30 June<br/>2019</b> |
|-------------------------------------------------|-------------------------------------|-------------------------------------|
| <b>Opening balance</b>                          | <b>162.195</b>                      | <b>198.003</b>                      |
| Taxes netted from funds recognised under equity | 9.123                               | 13.783                              |
| Currency translation differences                | (2.434)                             | 2.069                               |
| Deferred tax (income)/expense                   | (85.230)                            | 4.094                               |
|                                                 | <b>83.654</b>                       | <b>217.949</b>                      |

As of 30 June 2020, the Group calculated deferred tax assets of TL 81.314 thousand for deductible tax losses in the consolidated financial statements for the current year (31 December 2019: TL 75.059 thousand). The maturities of these losses are as follows:

|              | <b>30 June 2020</b> | <b>31 December 2019</b> |
|--------------|---------------------|-------------------------|
| 2025         | 81.314              | 75.059                  |
| <b>Total</b> | <b>81.314</b>       | <b>75.059</b>           |

**Corporate tax**

The Company and its Turkish subsidiaries are subject to Turkish corporate taxes. Provision is made in the accompanying financial statements for the estimated charge based on the Group's results for the period.

Corporate tax is applied on taxable corporate income, which is calculated from the statutory accounting profit by adding back non-deductible expenses, and by deducting dividends received from resident companies, other exempt income and investment incentives utilized.

The tax rate as of 30 June 2020 is 22% (2019: 22%).

In Turkey, advance tax returns are filed on a quarterly basis. The advance corporate income tax rate is 22% in 2020 (2019: 22%).

Losses are allowed to be carried five years maximum to be deducted from the taxable profit of the following years. However, losses occurred cannot be deducted from the profit occurred in the prior year's retroactively.

In Turkey, there is no procedure for a final and definitive agreement on tax assessments. Companies file their tax returns between 1st-25th of April following the close of the accounting year to which they relate. The companies with special accounting periods, file their tax returns between 1st-25th of fourth month after fiscal year end. Tax authorities may, however, examine such returns and the underlying accounting records and may revise assessments within five years.

In Turkey, the tax legislation does not permit to file a consolidated tax return. Therefore, provision for taxes, as reflected in the consolidated financial statements, has been calculated on a separate-entity basis.

The corporate tax in Egypt where Hi-Food for Advanced Food Industries and Ulker for Trading and Marketing, a subsidiary of the Group is 22,5% (2019: 22,5%). The corporate tax rate in Saudi Arabia where Food Manufacturers' Company and International Biscuits Company, subsidiaries of the Group is 20% (2019: 20%).

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**  
**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**  
**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2020**

(Amounts expressed in thousands of Turkish Lira (“TL”) unless otherwise stated)

**21. TAX ASSET AND LIABILITIES (Continued)**

Corporate tax (Continued)

The corporate tax in Kazakhstan where Hamle Company Ltd LLP, a subsidiary of the Group is 20% (2019: 20%).

The corporate tax in Kyrgyzstan where Ülker Star LLC, a subsidiary of the Group is 10% (2019: 10%).

In UAE where Amir Global Trading FZE, a subsidiary of the Group is exempt from corporate tax earnings (2019: exempt).

Income withholding tax

In addition to corporate taxes, companies should also calculate income withholding taxes and funds surcharge on any dividends distributed, except for companies receiving dividends who are Turkish residents and Turkish branches of foreign companies. Income withholding tax applied in between 24 April 2003 – 22 July 2006 is 10% and commencing from 22 July 2006, this rate has been changed to 15% upon the Council of Ministers’ Resolution No: 2006/10731. Undistributed dividends incorporated in share capital are not subject to income withholding tax.

Provision for taxation as of 30 June 2020 and 31 December 2019 is as follows:

|                                      | <b>30 June 2020</b> | <b>31 December 2019</b> |
|--------------------------------------|---------------------|-------------------------|
| Total corporate tax provision        | (201.400)           | (232.123)               |
| Prepaid taxes and funds              | 57.495              | 163.156                 |
| Taxation in the balance sheet        | <b>(143.905)</b>    | <b>(68.967)</b>         |
|                                      |                     |                         |
|                                      | <b>30 June 2020</b> | <b>31 December 2019</b> |
| Current period corporate tax expense | 201.400             | 115.593                 |
| Deferred tax (income)/expense        | (85.230)            | 4.094                   |
| Tax expense in the income statement  | <b>116.170</b>      | <b>119.687</b>          |

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**  
**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**22. EARNINGS PER SHARE**

A summary of the Group's weighted average number of shares outstanding as of 30 June 2020 and 2019 and computation of earnings per share set out here as follows:

|                                                     | <b>1 January -<br/>30 June<br/>2020</b> | <b>1 January -<br/>30 June<br/>2019</b> |
|-----------------------------------------------------|-----------------------------------------|-----------------------------------------|
| Weighted average number of common stock outstanding | 34.200.000                              | 34.200.000                              |
| Net profit                                          | 406.151                                 | 487.209                                 |
| <b>Basic Earnings per Share</b>                     | <b>1,19</b>                             | <b>1,42</b>                             |

**23. BALANCES AND TRANSACTIONS WITH RELATED PARTIES**

The detail of receivables from related parties is as follows:

|                       | <b>30 June 2020</b> | <b>31 December 2019</b> |
|-----------------------|---------------------|-------------------------|
| Trade receivables     | 2.296.692           | 2.106.741               |
| Non-trade receivables | 115.748             | 115.619                 |
|                       | <b>2.412.440</b>    | <b>2.222.360</b>        |

The detail of trade and non-trade receivables is as follows:

|                                                               | <b>30 June 2020</b> |                  | <b>31 December 2019</b> |                  |
|---------------------------------------------------------------|---------------------|------------------|-------------------------|------------------|
|                                                               | <b>Trade</b>        | <b>Non-Trade</b> | <b>Trade</b>            | <b>Non-Trade</b> |
| <b>Other Companies Controlled by the Ultimate Shareholder</b> |                     |                  |                         |                  |
| Horizon Hızlı Tük. Ür. Paz. Sat. ve Tic. A.Ş.                 | 957.583             | -                | 901.132                 | -                |
| Pasifik Tük. Ürün. Satış ve Ticaret A.Ş.                      | 602.155             | -                | 585.481                 | -                |
| Yeni Teközel Markalı Ürünler Dağıtım Hizmetleri A.Ş.          | 181.298             | -                | 159.344                 | -                |
| G2M Eksper Satış ve Dağıtım Hizmetleri A.Ş.                   | 85.073              | -                | 70.794                  | -                |
| United Biscuits (UK) Ltd.                                     | 3.103               | -                | 2.788                   | -                |
| Other (*)                                                     | 56.123              | 115.748          | 51.809                  | 115.619          |
| <b>Other Related parties</b>                                  |                     |                  |                         |                  |
| İstanbul Gıda Dış Ticaret A.Ş.                                | 411.357             | -                | 335.393                 | -                |
|                                                               | <b>2.296.692</b>    | <b>115.748</b>   | <b>2.106.741</b>        | <b>115.619</b>   |

(\*) TL 114.855 thousand of portion of other receivables is araised from the sales of İstanbul Gıda Dış Ticaret A.Ş.

The Group's trade receivables from related parties mainly arise from sales to Horizon Hızlı Tüketim Ürünleri Pazarlama Satış ve Tic. A.Ş. and Pasifik Tük. Ürün. Satış ve Ticaret A.Ş those performs sales and distribution of products though out Turkey and İstanbul Gıda Dış Ticaret A.Ş. those performs sales and distribution of products throughout which carries out the and distribution abroad.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**  
**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**23. BALANCES AND TRANSACTIONS WITH RELATED PARTIES (Continued)**

The detail of advances given to related parties is as follow:

|                             | <b>30 June 2020</b> | <b>31 December 2019</b> |
|-----------------------------|---------------------|-------------------------|
| Önem Gıda San. ve Tic. A.Ş. | 44.307              | 41.545                  |
|                             | <b>44.307</b>       | <b>41.545</b>           |

The detail of payables to related parties is as follows:

|                    | <b>30 June 2020</b> | <b>31 December 2019</b> |
|--------------------|---------------------|-------------------------|
| Trade payables     | 398.629             | 607.365                 |
| Non-trade payables | 1.523               | 113                     |
|                    | <b>400.152</b>      | <b>607.478</b>          |

The detail of trade and non-trade payables to related parties is as follows:

|                                                                | <b>30 June 2020</b> |                  | <b>31 December 2019</b> |                  |
|----------------------------------------------------------------|---------------------|------------------|-------------------------|------------------|
|                                                                | <b>Trade</b>        | <b>Non-Trade</b> | <b>Trade</b>            | <b>Non-Trade</b> |
| <b>Principle Shareholder</b>                                   |                     |                  |                         |                  |
| Yıldız Holding A.Ş.                                            | 81.904              | -                | 96.125                  | -                |
| <b>Other Companies Controlled by the Principle Shareholder</b> |                     |                  |                         |                  |
| Önem Gıda San. ve Tic. A.Ş.                                    | 136.397             | 13               | 385.307                 | -                |
| United Biscuits (UK) Ltd.                                      | 33.378              | 1.330            | 7.925                   | -                |
| Besler Gıda ve Kimya San. ve Tic. A.Ş.                         | 16.638              | -                | 8.466                   | -                |
| pladis Foods Limited                                           | 8.178               | -                | 4.491                   | -                |
| Adapazarı Şeker Fabrikası A.Ş.                                 | 4.448               | -                | 8.268                   | -                |
| Marsa Yağ San. ve Tic. A.Ş.                                    | 2.923               | -                | 2.409                   | -                |
| CCC Gıda San. ve Tic. A.Ş.                                     | 569                 | -                | 564                     | -                |
| Other                                                          | 25.970              | -                | 20.752                  | 9                |
| <b>Other related parties</b>                                   |                     |                  |                         |                  |
| İstanbul Gıda Dış Ticaret A.Ş.                                 | 88.224              | 180              | 73.058                  | 104              |
|                                                                | <b>398.629</b>      | <b>1.523</b>     | <b>607.365</b>          | <b>113</b>       |

The detail of due to related parties as loan payable is as follows:

|                     | <b>30 June 2020</b> | <b>31 December 2019</b> |
|---------------------|---------------------|-------------------------|
| Yıldız Holding A.Ş. | 102.123             | 84.327                  |
|                     | <b>102.123</b>      | <b>84.327</b>           |

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**  
**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED  
30 JUNE 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**23. BALANCES AND TRANSACTIONS WITH RELATED PARTIES (Continued)**

The detail of purchases from and sales to related parties is as follows:

|                                                                      | <b>1 January - 30 June 2020</b> |                  | <b>1 April- 30 June 2020</b> |                  | <b>1 January – 30 June 2019</b> |                  | <b>1 April- 30 June 2019</b> |                  |
|----------------------------------------------------------------------|---------------------------------|------------------|------------------------------|------------------|---------------------------------|------------------|------------------------------|------------------|
|                                                                      | <b>Purchases</b>                | <b>Sales</b>     | <b>Purchases</b>             | <b>Sales</b>     | <b>Purchases</b>                | <b>Sales</b>     | <b>Purchases</b>             | <b>Sales</b>     |
| <b><i>Other Companies Controlled by the Ultimate Shareholder</i></b> |                                 |                  |                              |                  |                                 |                  |                              |                  |
| Önem Gıda San. ve Tic. A.Ş.                                          | 1.129.029                       | 253              | 552.559                      | 119              | 954.862                         | 558              | 463.079                      | 246              |
| Besler Gıda ve Kimya San. ve Tic. A.Ş.                               | 159.718                         | 33               | 77.620                       | -                | 120.818                         | 89               | 55.326                       | 89               |
| United Biscuits (UK) Ltd.                                            | 51.598                          | 2.784            | 27.296                       | 1.871            | 54.081                          | 53.127           | 26.789                       | 22.047           |
| CCC Gıda San. ve Tic. A.Ş.                                           | 30                              | 908              | 16                           | 899              | 27.049                          | 47               | 15.213                       | 17               |
| Marsa Yağ San. ve Tic. A.Ş.                                          | 42.777                          | -                | 22.346                       | -                | 31.547                          | -                | 13.581                       | -                |
| Pendik Nişasta San. A.Ş.                                             | 20.882                          | -                | 6.336                        | -                | 24.641                          | -                | 11.245                       | -                |
| Horizon Hızlı Tük. Ür. Paz. Sat. ve Tic. A.Ş.                        | 4                               | 1.558.285        | -                            | 738.946          | 91                              | 1.426.713        | -                            | 689.228          |
| Pasifik Tüketim Ürünleri Satış ve Tic. A.Ş.                          | -                               | 952.025          | -                            | 442.027          | -                               | 696.113          | -                            | 346.750          |
| Yeni Teközel Markalı Ürünler Dağıtım Hizmetleri A.Ş.                 | -                               | 132.595          | -                            | 53.692           | -                               | 127.035          | -                            | 53.383           |
| Other                                                                | 18.232                          | 103.969          | 11.999                       | 44.659           | 10.459                          | 158.902          | 5.348                        | 76.118           |
| <b><i>Other related parties</i></b>                                  |                                 |                  |                              |                  |                                 |                  |                              |                  |
| İstanbul Gıda Dış Tic. A.Ş.                                          | 115.401                         | 579.534          | 41.295                       | 301.586          | -                               | -                | -                            | -                |
|                                                                      | <b>1.537.671</b>                | <b>3.330.386</b> | <b>739.647</b>               | <b>1.583.799</b> | <b>1.223.548</b>                | <b>2.462.584</b> | <b>590.581</b>               | <b>1.187.878</b> |

The Group mainly acquires raw materials from Besler Gıda ve Kimya Sanayi ve Ticaret A.Ş, which produces vegetable oil and margarine, Önem Gıda San. ve Tic. A.Ş and Pendik Nişasta San. A.Ş.. The major part of selling and distribution operations of the Group in Turkey are operated by Horizon Hızlı Tüketim Ürünleri Pazarlama Satış ve Tic. A.Ş. and Pasifik Tük. Ürün. Satış ve Ticaret and export sales operated by İstanbul Gıda Dış Tic. A.Ş..

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**  
**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**23. BALANCES AND TRANSACTIONS WITH RELATED PARTIES (Continued)**

The detail of income and expenses pertaining to interest, rent and services arising from transactions with related parties is as follows;

For the six months period ended 30 June 2020:

|                                                                    | Rent<br>Income/(Expense)<br>Net | Service<br>Income/(Expense)<br>Net | Interest and<br>Foreign<br>Exchange<br>Income/(Expense)<br>Net |
|--------------------------------------------------------------------|---------------------------------|------------------------------------|----------------------------------------------------------------|
| <b>Principle Shareholder</b>                                       |                                 |                                    |                                                                |
| Yıldız Holding A.Ş.                                                | 8                               | (110.051)                          | 17.432                                                         |
| <b>Other Companies Controlled by the<br/>Principle Shareholder</b> |                                 |                                    |                                                                |
| pladis Foods Limited                                               | -                               | (50.228)                           | -                                                              |
| Horizon Hızlı Tük. Ür. Paz. Sat. ve Tic. A.Ş.                      | -                               | (6.736)                            | 24.784                                                         |
| Pasifik Tüketim Ürünleri Satış ve Tic. A.Ş.                        | 36                              | (5.434)                            | 10.039                                                         |
| United Biscuits (UK) Ltd.                                          | -                               | (5.133)                            | 249                                                            |
| Önem Gıda San. ve Tic. A.Ş.                                        | 1.559                           | (7.192)                            | 5.016                                                          |
| İzsal Gayrimenkul Geliştirme A.Ş.                                  | (787)                           | (1.431)                            | -                                                              |
| Besler Gıda ve Kimya San. ve Tic. A.Ş.                             | -                               | (4)                                | (113)                                                          |
| CCC Gıda San. ve Tic. A.Ş.                                         | (426)                           | (239)                              | -                                                              |
| Other                                                              | 748                             | (8.051)                            | (6.610)                                                        |
| <b>Other related parties</b>                                       |                                 |                                    |                                                                |
| İstanbul Gıda Dış Ticaret A.Ş.                                     | -                               | 950                                | 85.758                                                         |
|                                                                    | <b>1.138</b>                    | <b>(193.549)</b>                   | <b>136.555</b>                                                 |

For the three months between 1 April - 30 June 2020 periods:

|                                                                    | Rent<br>Income/(Expense)<br>Net | Service<br>Income/(Expense)<br>Net | Interest and<br>Foreign Exchange<br>Income/(Expense)<br>Net |
|--------------------------------------------------------------------|---------------------------------|------------------------------------|-------------------------------------------------------------|
| <b>Principle Shareholder</b>                                       |                                 |                                    |                                                             |
| Yıldız Holding A.Ş.                                                | 2                               | (52.683)                           | 7.002                                                       |
| <b>Other Companies Controlled by the<br/>Principle Shareholder</b> |                                 |                                    |                                                             |
| pladis Foods Limited                                               | -                               | (35.632)                           | -                                                           |
| Önem Gıda San. ve Tic. A.Ş.                                        | 780                             | (4.455)                            | 2.554                                                       |
| Pasifik Tüketim Ürünleri Satış ve Tic. A.Ş.                        | 18                              | (3.542)                            | 4.945                                                       |
| Horizon Hızlı Tük. Ür. Paz. Sat. ve Tic. A.Ş.                      | -                               | (2.961)                            | 12.627                                                      |
| United Biscuits (UK) Ltd.                                          | -                               | (1.706)                            | 120                                                         |
| İzsal Gayrimenkul Geliştirme A.Ş.                                  | (392)                           | (692)                              | -                                                           |
| CCC Gıda San. ve Tic. A.Ş.                                         | (212)                           | (123)                              | -                                                           |
| Other                                                              | 357                             | (6.652)                            | (3.581)                                                     |
| <b>Other related parties</b>                                       |                                 |                                    |                                                             |
| İstanbul Gıda Dış Tic. A.Ş.                                        | -                               | 663                                | 35.003                                                      |
|                                                                    | <b>553</b>                      | <b>(107.783)</b>                   | <b>58.670</b>                                               |

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**  
**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**23. BALANCES AND TRANSACTIONS WITH RELATED PARTIES (Continued)**

For the six months period ended 30 June 2019:

|                                                                    | <b>Rent<br/>Income/(Expense)<br/>Net</b> | <b>Service<br/>Income/(Expense)<br/>Net</b> | <b>Interest and Foreign<br/>Exchange<br/>Income/(Expense)<br/>Net</b> |
|--------------------------------------------------------------------|------------------------------------------|---------------------------------------------|-----------------------------------------------------------------------|
| <b>Principle Shareholder</b>                                       |                                          |                                             |                                                                       |
| Yıldız Holding A.Ş.                                                | (114)                                    | (97.028)                                    | (13.507)                                                              |
| <b>Other Companies Controlled by the<br/>Principle Shareholder</b> |                                          |                                             |                                                                       |
| Önem Gıda San. ve Tic. A.Ş.                                        | 1.447                                    | (6.117)                                     | 2.518                                                                 |
| Horizon Hızlı Tük. Ür. Paz. Sat. ve Tic. A.Ş.                      | 16                                       | (11.666)                                    | 58.406                                                                |
| Pasifik Tüketim Ürünleri Satış ve Tic. A.Ş.                        | 53                                       | (9.862)                                     | 29.240                                                                |
| United Biscuits (UK) Ltd.                                          | 9                                        | (1.004)                                     | 1.079                                                                 |
| İzsal Gayrimenkul Geliştirme A.Ş.                                  | (993)                                    | (1.034)                                     | -                                                                     |
| CCC Gıda San. ve Tic. A.Ş.                                         | (376)                                    | 1.277                                       | (894)                                                                 |
| Besler Gıda ve Kimya San. ve Tic. A.Ş.                             | -                                        | (179)                                       | (1.116)                                                               |
| Other                                                              | 872                                      | (2.905)                                     | 7.037                                                                 |
|                                                                    | <b>914</b>                               | <b>(128.518)</b>                            | <b>82.763</b>                                                         |

For the three months between 1 April - 30 June 2019 periods:

|                                                                    | <b>Rent<br/>Income/(Expense)<br/>Net</b> | <b>Service<br/>Income/(Expense)<br/>Net</b> | <b>Interest and Foreign<br/>Exchange<br/>Income/(Expense)<br/>Net</b> |
|--------------------------------------------------------------------|------------------------------------------|---------------------------------------------|-----------------------------------------------------------------------|
| <b>Principle Shareholder</b>                                       |                                          |                                             |                                                                       |
| Yıldız Holding A.Ş.                                                | (23)                                     | (47.235)                                    | (18.653)                                                              |
| <b>Other Companies Controlled by the<br/>Principle Shareholder</b> |                                          |                                             |                                                                       |
| Önem Gıda San. ve Tic. A.Ş.                                        | 807                                      | (1.360)                                     | 1.664                                                                 |
| Horizon Hızlı Tük. Ür. Paz. Sat. ve Tic. A.Ş.                      | 8                                        | (8.270)                                     | 38.655                                                                |
| Pasifik Tüketim Ürünleri Satış ve Tic. A.Ş.                        | 17                                       | (5.865)                                     | 18.185                                                                |
| United Biscuits (UK) Ltd.                                          | -                                        | (946)                                       | (924)                                                                 |
| İzsal Gayrimenkul Geliştirme A.Ş.                                  | (501)                                    | (573)                                       | -                                                                     |
| CCC Gıda San. ve Tic. A.Ş.                                         | (189)                                    | 864                                         | (246)                                                                 |
| Other                                                              | 461                                      | (2.841)                                     | 1.568                                                                 |
|                                                                    | <b>580</b>                               | <b>(66.226)</b>                             | <b>40.249</b>                                                         |

Benefits provided to members of BOD and key management personnel:

|                                    | <b>30 June 2020</b> | <b>31 December 2019</b> |
|------------------------------------|---------------------|-------------------------|
| Fees and other short-term benefits | 21.241              | 19.816                  |
|                                    | <b>21.241</b>       | <b>19.816</b>           |

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS**

**ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**24. NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENT**

Foreign currency risk management

Transactions in foreign currencies expose the Group to foreign currency risk.

This risk mainly arises from fluctuation of foreign currency used in conversion of foreign assets and liabilities into Turkish Lira. Foreign currency risk arises as a result of trading transactions in the future and the difference between the assets and liabilities recognized. In this regard, the Group manages this risk with a method of netting foreign currency denominated assets and liabilities. The management reviews the foreign currency open position and provides measures when needed. The group mainly faces USD, EUR, GBP, CHF and DKK currency risks.

The foreign currency denominated assets and liabilities of monetary and non-monetary items are as follows:

|                                                                                                      | <b>30 June 2020</b> |                |                  |              |             |
|------------------------------------------------------------------------------------------------------|---------------------|----------------|------------------|--------------|-------------|
|                                                                                                      | <b>TL</b>           | <b>USD</b>     | <b>EUR</b>       | <b>GBP</b>   | <b>CHF</b>  |
| 1. Trade Receivables                                                                                 | 383.260             | 47.017         | 5.431            | 2.337        | -           |
| 2a. Monetary Financial Assets                                                                        | 6.697.738           | 885.332        | 82.408           | 568          | 16          |
| 2b. Non-Monetary Financial Assets                                                                    | -                   | -              | -                | -            | -           |
| 3. Other                                                                                             | 10.463              | 445            | 935              | 25           | -           |
| 4. CURRENT ASSETS                                                                                    | <b>7.091.461</b>    | <b>932.794</b> | <b>88.774</b>    | <b>2.930</b> | <b>16</b>   |
| 5. Trade Receivables                                                                                 | -                   | -              | -                | -            | -           |
| 6a. Monetary Financial Assets                                                                        | -                   | -              | -                | -            | -           |
| 6b. Non-Monetary Financial Assets                                                                    | -                   | -              | -                | -            | -           |
| 7. Other                                                                                             | 1.359               | 41             | 148              | (16)         | 10          |
| 8. NON-CURRENT ASSETS                                                                                | <b>1.359</b>        | <b>41</b>      | <b>148</b>       | <b>(16)</b>  | <b>10</b>   |
| 9. TOTAL ASSETS                                                                                      | <b>7.092.820</b>    | <b>932.835</b> | <b>88.922</b>    | <b>2.914</b> | <b>26</b>   |
| 10. Trade Payables                                                                                   | 141.024             | 12.856         | 5.557            | 1.126        | 102         |
| 11. Financial Liabilities                                                                            | 3.318.981           | 116.528        | 327.142          | -            | -           |
| 12a. Other Monetary Financial Liabilities                                                            | 940                 | -              | 122              | -            | -           |
| 12b. Other Non-monetary Financial Liabilities                                                        | 1.124               | 82             | 73               | -            | -           |
| 13. CURRENT LIABILITIES                                                                              | <b>3.462.069</b>    | <b>129.466</b> | <b>332.894</b>   | <b>1.126</b> | <b>102</b>  |
| 14. Trade Payables                                                                                   | -                   | -              | -                | -            | -           |
| 15. Financial Liabilities                                                                            | 3.445.115           | 104.873        | 353.851          | -            | -           |
| 16a. Other Monetary Financial Liabilities                                                            | -                   | -              | -                | -            | -           |
| 17. NON-CURRENT LIABILITIES                                                                          | <b>3.445.115</b>    | <b>104.873</b> | <b>353.851</b>   | <b>-</b>     | <b>-</b>    |
| 18. TOTAL LIABILITIES                                                                                | <b>6.907.184</b>    | <b>234.339</b> | <b>686.745</b>   | <b>1.126</b> | <b>102</b>  |
| 19. Net Assets of Off Statement of Financial Position (19a-19b)                                      | -                   | -              | -                | -            | -           |
| 19a. Net Assets of Off Statement of Financial Position                                               | -                   | -              | -                | -            | -           |
| 19b. Net Liabilities of Off Statement of Financial Position                                          | -                   | -              | -                | -            | -           |
| 20. Net Foreign Currency Asset / (Liability) Position (9-18+19)                                      | <b>185.636</b>      | <b>698.496</b> | <b>(597.823)</b> | <b>1.788</b> | <b>(76)</b> |
| 21. Monetary Items Net Foreign Currency Asset / (Liability) Position (1+2a+5+6a-10-11-12a-14-15-16a) | <b>174.938</b>      | <b>698.092</b> | <b>(598.833)</b> | <b>1.779</b> | <b>(86)</b> |
| 22. Total Fair Value of Financial Instruments Used to Hedge the Foreign Currency Position            | -                   | -              | -                | -            | -           |
| 23. Total value of Hedged Foreign Currency Assets                                                    | -                   | -              | -                | -            | -           |
| 24. Total value of Hedged Foreign Currency Liabilities                                               | -                   | -              | -                | -            | -           |

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS**

**ORIGINALLY ISSUED IN TURKISH**

**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**24. NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENTS (Continued)**

*Foreign Currency Risk Management (continued)*

|                                                                                                      | 31 December 2019 |                |                  |              |              |
|------------------------------------------------------------------------------------------------------|------------------|----------------|------------------|--------------|--------------|
|                                                                                                      | TL               | USD            | EUR              | GBP          | CHF          |
| 1. Trade Receivables                                                                                 | 383.292          | 51.020         | 8.896            | 2.708        | -            |
| 2a. Monetary Financial Assets                                                                        | 5.388.027        | 901.935        | 3.636            | 785          | 11           |
| 2b. Non-Monetary Financial Assets                                                                    | -                | -              | -                | -            | -            |
| 3. Other                                                                                             | 5.179            | 268            | 522              | 14           | 1            |
| 4. CURRENT ASSETS                                                                                    | <b>5.776.498</b> | <b>953.223</b> | <b>13.054</b>    | <b>3.507</b> | <b>12</b>    |
| 5. Trade Receivables                                                                                 | -                | -              | -                | -            | -            |
| 6a. Monetary Financial Assets                                                                        | -                | -              | -                | -            | -            |
| 6b. Non-Monetary Financial Assets                                                                    | -                | -              | -                | -            | -            |
| 7. Other                                                                                             | -                | -              | -                | -            | -            |
| 8. NON-CURRENT ASSETS                                                                                | -                | -              | -                | -            | -            |
| 9. TOTAL ASSETS                                                                                      | <b>5.776.498</b> | <b>953.223</b> | <b>13.054</b>    | <b>3.507</b> | <b>12</b>    |
| 10. Trade Payables                                                                                   | 100.636          | 10.497         | 4.454            | 917          | 251          |
| 11. Financial Liabilities                                                                            | 5.124.763        | 259.148        | 539.105          | -            | -            |
| 12a. Other Monetary Financial Liabilities                                                            | 7.751            | 1.166          | 124              | -            | -            |
| 12b. Other Non-monetary Financial Liabilities                                                        | 2.867            | 393            | 80               | -            | -            |
| 13. CURRENT LIABILITIES                                                                              | <b>5.236.017</b> | <b>271.204</b> | <b>543.763</b>   | <b>917</b>   | <b>251</b>   |
| 14. Trade Payables                                                                                   | -                | -              | -                | -            | -            |
| 15. Financial Liabilities                                                                            | 379.467          | -              | 57.058           | -            | -            |
| 16a. Other Monetary Financial Liabilities                                                            | -                | -              | -                | -            | -            |
| 17. NON-CURRENT LIABILITIES                                                                          | <b>379.467</b>   | -              | <b>57.058</b>    | -            | -            |
| 18. TOTAL LIABILITIES                                                                                | <b>5.615.484</b> | <b>271.204</b> | <b>600.821</b>   | <b>917</b>   | <b>251</b>   |
| 19. Net Assets of Off Statement of Financial Position (19a-19b)                                      | <b>888.581</b>   | <b>116.000</b> | <b>30.000</b>    | -            | -            |
| 19a. Net Assets of Off Statement of Financial Position                                               | -                | -              | -                | -            | -            |
| 19b. Net Liabilities of Off Statement of Financial Position                                          | (888.581)        | (116.000)      | (30.000)         | -            | -            |
| 20. Net Foreign Currency Asset / (Liability) Position (9-18+19)                                      | <b>1.049.595</b> | <b>798.019</b> | <b>(557.767)</b> | <b>2.590</b> | <b>(239)</b> |
| 21. Monetary Items Net Foreign Currency Asset / (Liability) Position (1+2a+5+6a-10-11-12a-14-15-16a) | <b>158.702</b>   | <b>682.144</b> | <b>(588.209)</b> | <b>2.576</b> | <b>(240)</b> |
| 22. Total Fair Value of Financial Instruments Used to Hedge the Foreign Currency Position            | 358.919          | 46.403         | 12.522           | -            | -            |
| 23. Total value of Hedged Foreign Currency Assets                                                    | -                | -              | -                | -            | -            |
| 24. Total value of Hedged Foreign Currency Liabilities                                               | -                | -              | -                | -            | -            |

The Group's export and import balances in the periods of 30 June 2020 and 2019 are as follows:

|               | 1 January – 30 June 2020 | 1 January – 30 June 2019 |
|---------------|--------------------------|--------------------------|
| Total exports | 880.002                  | 804.645                  |
| Total imports | 317.990                  | 186.629                  |
|               | <b>1.197.992</b>         | <b>991.274</b>           |

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS****ORIGINALLY ISSUED IN TURKISH****ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES****NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED 30 JUNE 2020**

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**24. NATURE AND LEVEL OF RISKS DERIVED FROM FINANCIAL INSTRUMENTS (Continued)***Foreign currency risk sensitivity*

The Group is exposed to foreign exchange risk arising primarily from USD and EUR. The table below shows, the foreign currency sensitivity of the Company arising from 10% change in US dollar and EUR rates. The rate used as 10% is a fair benchmark for the Company as it is limited to capital commitment threshold. This rate is the anticipated rate change of the Company's senior management. Sensitivity analysis includes only the monetary items in foreign currency at year end and shows the effect of 10% increase in USD and in EUR foreign currency rates. Negative value implies the effect of 10% increase in USD and in EUR foreign currency rates against TL on the decrease in the net profit.

|                                               | <b>30 June 2020</b>                             |                                                 | <b>30 June 2019</b>                             |                                                 |
|-----------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
|                                               | <b>Income / Expense</b>                         |                                                 | <b>Income / Expense</b>                         |                                                 |
|                                               | <b>Appreciation<br/>of foreign<br/>currency</b> | <b>Depreciation<br/>of foreign<br/>currency</b> | <b>Appreciation<br/>of foreign<br/>currency</b> | <b>Depreciation<br/>of foreign<br/>currency</b> |
| In case of %10 appreciation of USD against TL |                                                 |                                                 |                                                 |                                                 |
| 1 - US Dollar net asset / liability           | 477.649                                         | (477.649)                                       | 379.314                                         | (379.314)                                       |
| 2- Part of hedged from US<br>Dollar risk (-)  |                                                 |                                                 |                                                 |                                                 |
| <b>3- US Dollar net effect (1 +2)</b>         | <b>477.649</b>                                  | <b>(477.649)</b>                                | <b>379.314</b>                                  | <b>(379.314)</b>                                |
| In case of %10 appreciation of EUR against TL |                                                 |                                                 |                                                 |                                                 |
| 4 -Euro net asset / liability                 | (461.592)                                       | 461.592                                         | (365.481)                                       | 365.481                                         |
| 5 - Part of hedged from Euro<br>risk (-)      |                                                 |                                                 |                                                 |                                                 |
| <b>6- Euro net effect (4+5)</b>               | <b>(461.592)</b>                                | <b>461.592</b>                                  | <b>(365.481)</b>                                | <b>365.481</b>                                  |
| <b>Total (3 + 6)</b>                          | <b>16.057</b>                                   | <b>(16.057)</b>                                 | <b>13.833</b>                                   | <b>(13.833)</b>                                 |

**25. FINANCIAL INSTRUMENTS****Fair Value of Financial Assets**

Fair value measurements by level of the following fair value measurement hierarchy is as follows:

Level 1: Quoted prices in active markets for identical assets or liabilities

Level 2: Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices).

Level 3: Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs)

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONDENSED FINANCIAL STATEMENTS**  
**ORIGINALLY ISSUED IN TURKISH**  
**ÜLKER BİSKÜVİ SANAYİ A.Ş. AND ITS SUBSIDIARIES**  
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS FOR THE INTERIM PERIOD ENDED  
30 JUNE 2020

(Amounts expressed in thousands of Turkish Lira ("TL") unless otherwise stated)

**25. FINANCIAL INSTRUMENTS (Continued)**

**Fair Value of Financial Assets (continued)**

The classification of the Company's financial assets and liabilities at fair value is as follows:

|                                                                               | 30 June<br>2020  | Fair value hierarchy<br>as of reporting date |                  |                  |
|-------------------------------------------------------------------------------|------------------|----------------------------------------------|------------------|------------------|
|                                                                               |                  | Level 1<br>TL                                | Level 2<br>TL    | Level 3<br>TL    |
| <b>Financial assets</b>                                                       |                  |                                              |                  |                  |
| Financial assets at fair value through<br>profit and loss                     |                  |                                              |                  |                  |
| - Available for sale                                                          | 3.605.728        | 779                                          | 3.600.667        | 4.282            |
| Financial assets at fair value through<br>comprehensive income statement      |                  |                                              |                  |                  |
| - Shares                                                                      | 1.107.845        | -                                            | -                | 1.107.845        |
| <b>Total</b>                                                                  | <b>5.821.418</b> | <b>779</b>                                   | <b>3.600.667</b> | <b>2.219.972</b> |
| <b>Financial liabilities</b>                                                  |                  |                                              |                  |                  |
| Financial liabilities at fair value through<br>comprehensive income statement |                  |                                              |                  |                  |
| - Derivative instruments                                                      | 781              | 781                                          | -                | -                |
| <b>Total</b>                                                                  | <b>781</b>       | <b>781</b>                                   | <b>-</b>         | <b>-</b>         |

  

|                                                                          | 31<br>December<br>2019 | Fair value hierarchy<br>as of reporting date |                  |                |
|--------------------------------------------------------------------------|------------------------|----------------------------------------------|------------------|----------------|
|                                                                          |                        | Level 1<br>TL                                | Level 2<br>TL    | Level 3<br>TL  |
| <b>Financial assets</b>                                                  |                        |                                              |                  |                |
| Financial assets at fair value through<br>comprehensive income statement |                        |                                              |                  |                |
| - Available for sale                                                     | 3.057.459              | 806                                          | 3.053.379        | 3.274          |
| Financial assets at fair value through<br>comprehensive income statement |                        |                                              |                  |                |
| - Shares                                                                 | 945.829                | -                                            | -                | 945.829        |
| - Derivative instruments                                                 | 358.919                | -                                            | 358.919          | -              |
| <b>Total</b>                                                             | <b>4.362.207</b>       | <b>806</b>                                   | <b>3.412.298</b> | <b>949.103</b> |

**26. EVENTS AFTER THE BALANCE SHEET DATE**

General Assembly Meeting of the Group for 2019 was held on 21 July 2020.